Antiphospholipid Syndrome

Complex MONDO:8000010 Pathograph 42 Show in embeddings browser Autoimmune Disease

An acquired systemic autoimmune thrombophilia in which persistent, clinically relevant antiphospholipid antibodies occur in association with arterial, venous, or microvascular thrombosis and/or defined pregnancy morbidity. Competing causes affect clinical attribution; antibody positivity without an associated manifestation is an aPL-carrier state, not "asymptomatic APS."

Ask OpenScientist

Ask a research question about Antiphospholipid Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Chapter

📘

Definitions

2023 ACR/EULAR APS classification criteria

A weighted research-classification system designed for high specificity. It is not a stand-alone diagnostic rule and should not override clinical judgment or exclude otherwise clinically diagnosed patients.

OTHER Research classification of people with suspected APS

Entry criterion

At least one positive aPL test must occur within three years of an aPL-associated clinical criterion.

Minimum required: 1

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion"

This is the temporal entry gate for applying the weighted criteria.

Weighted clinical and laboratory domains

After the entry criterion, classification requires at least three points from clinical domains and at least three points from laboratory domains. Clinical domains are macrovascular venous, macrovascular arterial, microvascular, obstetric, cardiac-valve, and hematologic; laboratory domains are lupus-anticoagulant functional assays and solid-phase aCL or anti-beta2GPI assays.

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS."

This gives the two independent score thresholds.

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR."

The stated purpose confines this tool to classification for research rather than clinical diagnosis.

2006 revised Sapporo (Sydney) classification criteria

The historical research criteria require at least one qualifying thrombosis or pregnancy-morbidity criterion and at least one qualifying laboratory criterion, with persistent aPL demonstrated on two tests at least 12 weeks apart. They remain clinically informative but are classification criteria.

OTHER Historical research classification of thrombotic or obstetric APS

Clinical criterion

At least one objectively documented vascular thrombosis or qualifying pregnancy-morbidity criterion is required.

Minimum required: 1

Show evidence (1 reference)

PMID:24461539 SUPPORT Other

"At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS."

This states the required clinical arm and distinguishes classification from diagnosis.

Persistent laboratory criterion

At least one qualifying lupus anticoagulant, IgG/IgM anticardiolipin, or IgG/IgM anti-beta2GPI result is required, with positivity demonstrated on two tests at least 12 weeks apart.

Minimum required: 1

Show evidence (2 references)

PMID:24461539 SUPPORT Other

This supplies the three laboratory families and the clinical-laboratory pairing.

PMID:37640450 SUPPORT Human Clinical

"the definition of aPL “persistence” (ie, 2 positive tests for aPL at least 12 weeks apart)"

This states the historical persistence interval retained in current criteria work.

Show evidence (1 reference)

PMID:24461539 SUPPORT Other

"The Sapporo criteria, as they are often called, were revised at another workshop in Sydney, Australia, in 2004, during the 11th International Congress on aPL."

This supports the historical Sydney revision represented by this definition.

◆

Subtypes

Primary antiphospholipid syndrome MONDO:0005204

APS occurring without another associated autoimmune disease.

Show evidence (1 reference)

PMID:27550302 SUPPORT Other

"APS can be isolated (primary APS) or associated with other autoimmune diseases."

This supports the primary-versus-associated distinction.

Secondary antiphospholipid syndrome MONDO:0021008

APS occurring with another autoimmune disease, most often systemic lupus erythematosus; the associated disease does not remove the requirement for clinical APS manifestations and persistent aPL.

Show evidence (1 reference)

PMID:27550302 SUPPORT Other

"APS can be isolated (primary APS) or associated with other autoimmune diseases."

This supports APS associated with another autoimmune disease.

Catastrophic antiphospholipid syndrome MONDO:0018737

A rare, life-threatening form with rapidly developing large- and small-vessel thrombosis at multiple sites and acute multiorgan dysfunction.

Show evidence (1 reference)

PMID:39644034 SUPPORT Other

"Catastrophic antiphospholipid syndrome (CAPS) is a rare but life-threatening form of antiphospholipid syndrome (APS) defined by the rapid onset of large and small vessel thrombosis occurring simultaneously across multiple sites, resulting in multiorgan dysfunction."

This provides the current clinical boundary for catastrophic APS.

Discussions and Knowledge Gaps

The antiphospholipid antibodies that define APS are pathogenic, yet the immune mechanisms that initiate and sustain their production remain poorly understood. Which upstream antigenic, environmental, or genetic trigger activates autoreactive aPL-specific CD4+ T cells, and is the observed CD4+ T cell dysregulation (Th1/Th17 skewing, diminished Treg, a disturbed Tfh/Tfr axis) a primary driver of aPL production or a secondary consequence of established autoimmunity? Do the contradictory subset findings across cohorts reflect true APS phenotypic heterogeneity or unresolved methodological confounding?

KNOWLEDGE GAP OPEN gap_aps_apl_production_cd4_dysregulation

Attached to

pathophysiology#CD4+ T cell dysregulation and autoreactive B cell licensing pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes pathophysiology#Cell-surface beta2GPI binding

aPL drive thrombosis and obstetric morbidity, but the autoimmune program that maintains chronic aPL production is unresolved, limiting mechanism-based therapy beyond anticoagulation. The Gaspar et al. (2026) review synthesizes candidate links between autoreactive aPL-specific CD4+ T cells and sustained aPL responses, alongside reports of Th1/Th17 polarization, reduced Treg frequency or function, and a dysregulated follicular T-cell (Tfh/Tfr) axis in primary APS. A deliberately non-directional CD4+ T-cell dysregulation node represents this evidence in the pathophysiology graph. However, two gaps persist. First, the upstream trigger that activates aPL-specific CD4+ T cells is unknown, so the pathophysiology lacks a defined event upstream of the CD4+ dysregulation node. Second, the literature disagrees on which CD4+ T cell subsets dominate, and it is unclear whether CD4+ T cell dysregulation causes aPL production or follows it. Resolving the directionality and the trigger would determine whether T-B crosstalk is a viable therapeutic target and whether distinct immune profiles define APS subtypes.

Proposed experiments

Longitudinal CD4+ T cell immunophenotyping with aPL-specific T cell tracking in primary APS

longitudinal immunophenotyping observational cohort study

exp_aps_cd4_longitudinal_apl_directionality

Enroll aPL-positive individuals spanning asymptomatic carriers, new-onset primary APS, and established primary APS, plus matched controls, and follow them longitudinally. At each visit, deep-immunophenotype circulating CD4+ T cell subsets (Th1, Th17, Treg, Tfh, Tfr, Tfh17-like) by spectral flow cytometry, quantify beta2GPI-reactive CD4+ T cells with antigen-specific assays, and measure aPL titres (anticardiolipin, anti-beta2GPI, lupus anticoagulant). Use standardized gating across sites to control the methodological variability the review highlights, and apply cross-lagged analysis to test whether T cell dysregulation precedes or follows changes in aPL titre.

Readouts

aPL-specific CD4+ T cell frequency and polarization

pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes

Measure the frequency and Th1/Th17/Tfh polarization of beta2GPI-reactive CD4+ T cells and test whether their expansion temporally precedes rising aPL titres, supporting a primary-driver role in autoantibody generation.

antigen-specific T cell stimulation assay spectral flow cytometry immunophenotyping

Direction: POSITIVE

Regulatory T and follicular regulatory cell deficit

pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes

Quantify Treg and Tfr frequency and suppressive function to test whether a regulatory deficit accompanies the loss of tolerance that permits sustained aPL production.

regulatory T cell suppression assay

Direction: NEGATIVE

aPL titre trajectory relative to T cell changes

pathophysiology#Cell-surface beta2GPI binding

Track anticardiolipin, anti-beta2GPI, and lupus anticoagulant levels and relate their trajectory to preceding CD4+ T cell subset shifts to resolve directionality between T cell dysregulation and pathogenic antibody availability for cell-surface binding.

antiphospholipid antibody titre assay

Direction: POSITIVE

Decision criterion

A primary-driver model is supported if expansion of aPL-specific CD4+ T cells and a Tfh/Tfr imbalance reproducibly precede rises in aPL titre in converters across sites; a secondary-consequence model is supported if T cell dysregulation appears only after aPL elevation. Reproducible, site-concordant subset signatures that segregate patients into distinct immune profiles would favor true phenotypic heterogeneity over methodological artifact.

Would support

pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes pathophysiology#Cell-surface beta2GPI binding

Show evidence (2 references)

PMID:42229606 SUPPORT Other

"While the clinical role of aPL is well established, the immune mechanisms sustaining their production remain poorly understood."

This review statement directly establishes that the mechanisms sustaining aPL production are unresolved, motivating the primary arm of this knowledge gap.

PMID:42229606 SUPPORT Other

"Despite inconsistent findings across studies, likely reflecting phenotypical APS heterogeneity, distinct aPL profiles, and immunophenotyping methodological variations, the cumulative data support a model in which APS involves a coordinated disruption of CD4+ T cell homeostasis, encompassing both..."

This passage documents the contradictory CD4+ T cell findings and the uncertainty over heterogeneity versus methodological confounding, motivating the secondary arm of this knowledge gap.

⚙

Pathophysiology

CD4+ T cell dysregulation and autoreactive B cell licensing

Altered helper, regulatory, and follicular CD4+ T-cell profiles are reported in primary APS, but whether they initiate persistent aPL production or arise after established autoimmunity remains unresolved.

helper T cell CL:0000912 regulatory T cell CL:0000815 T follicular helper cell CL:0002038

Downstream

Autoantibody generation against beta2GPI and phospholipid complexes Autoreactive CD4+ T-cell help is a plausible contributor to aPL-specific B-cell responses; human observations are associative and the upstream trigger is unknown.

Show evidence (2 references)

PMID:42229606 PARTIAL Human Clinical

"APS is skewed toward Th1 and Th17 polarization, diminished Treg frequency or function, and a dysregulated Tfh/Tfr axis. Specifically, increased activated Tfh cells alongside reduced Tfr cells and skewing toward Tfh17-like subsets, have been linked to increased aPL titres and disease burden."

The human associations support immune imbalance but do not show that it drives aPL production.

PMID:42229606 PARTIAL Other

"the cumulative data support a model in which APS involves a coordinated disruption of CD4+ T cell homeostasis, encompassing both effector and regulatory arms."

The authors propose a coordinated-imbalance model while explicitly noting inconsistent findings.

Autoantibody generation against beta2GPI and phospholipid complexes

Persistent aPL responses are heterogeneous but clinically important reactivity is commonly directed against phospholipid-binding proteins, especially beta2GPI. The immune events that initiate and sustain these responses are incompletely established.

B cell CL:0000236 T cell CL:0000084

immunoglobulin production GO:0002377

Downstream

Cell-surface beta2GPI binding Circulating aPL bind beta2GPI and phospholipid-associated targets on vascular and placental surfaces.

Antiphospholipid antibody positivity Autoantibody generation manifests clinically as antiphospholipid antibody positivity.

Anticardiolipin IgG antibody positivity Autoantibody generation includes anticardiolipin IgG antibodies.

Anticardiolipin IgM antibody positivity Autoantibody generation includes anticardiolipin IgM antibodies.

Lupus anticoagulant Autoantibody generation includes lupus anticoagulant activity detected in APS laboratory testing.

Anti-beta 2 glycoprotein I antibody positivity Autoantibody generation includes anti-beta2 glycoprotein I antibodies.

Anti-beta-2-Glycoprotein I IgG antibody positivity Autoantibody generation includes anti-beta2 glycoprotein I IgG antibodies.

Show evidence (2 references)

PMID:29867951 SUPPORT Other

"The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein β2 glycoprotein I (β2GPI) or that directly recognize negatively charged membrane phospholipids in a manner that may contribute to arterial or venous thrombosis."

This review supports aPL availability as an upstream disease feature while preserving antibody heterogeneity.

PMID:33722752 SUPPORT Other

"It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS)."

This supports the role of adaptive immune cells, especially B cells, in generating pathogenic antiphospholipid antibodies.

Cell-surface beta2GPI binding

Anti-beta2GPI/beta2GPI complexes can assemble along phospholipid-rich cell surfaces. Receptor usage and the importance of particular antibody specificities vary across experimental systems.

Downstream

Innate receptor signaling Surface-bound immune complexes engage receptors such as TLR4 and trigger downstream inflammatory signaling cascades.

Placental immune injury Beta2GPI-dependent antibodies can bind trophoblast and decidual surfaces and perturb placental-cell function without requiring placental thrombosis.

Show evidence (1 reference)

PMID:29867951 SUPPORT Other

"Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces."

This supports pathogenic antibody binding along cellular surfaces as a distinct intermediate APS event.

Innate receptor signaling

Experimental systems implicate TLR4, p38 MAPK, NF-kappaB, and related pathways after aPL-beta2GPI binding; no single receptor-signaling route has been established as universal across APS patients.

Downstream

Endothelial activation Intracellular signaling induces a proadhesive and procoagulant endothelial phenotype.

Monocyte tissue factor induction Signaling in monocytes induces tissue factor expression and amplifies coagulation.

Platelet activation Signaling promotes platelet activation and thromboxane-driven thrombus propagation.

Neutrophil extracellular-trap amplification Anti-beta2GPI can promote NET release, adding a neutrophil-mediated immunothrombotic amplifier.

Show evidence (2 references)

PMID:22055541 SUPPORT Other

"Diverse experimental evidence exists implicating the activation of various different cell surface receptors and intracellular pathways by antiphospholipid antibodies (aPL)."

This review supports a distinct signaling step between antibody binding and overt thrombosis.

PMID:22055541 SUPPORT Other

"TLR4, p38 MAPK and NFκB are involved in mediating pathogenic effects of aPL on different cell types and may be potential therapeutic targets in antiphospholipid syndrome."

This identifies a specific innate signaling axis activated by aPL-beta2GPI complexes.

Neutrophil extracellular-trap amplification

APS neutrophils can release excess neutrophil extracellular traps (NETs), whose chromatin and granule proteins provide a candidate immunothrombotic scaffold. Human, in-vitro, and animal observations support this amplifier, but do not establish NETs as necessary in every thrombotic event.

neutrophil CL:0000775

neutrophil extracellular trap formation GO:0140645

Downstream

Arterial and venous thrombosis NET-derived material can amplify coagulation and thrombus growth.

Show evidence (1 reference)

PMID:29867951 SUPPORT Model Organism

"In animal models, inhibitors of NET release show promise in reducing thrombus formation, and mice deficient for PAD4, the enzyme that deiminates histones and promotes DNA unraveling in NETs, are resistant to pro-thrombotic stimuli"

Experimental perturbation supports a mechanistic contribution from NET formation.

Endothelial activation

aPL signaling converts endothelial cells into a proadhesive, inflammatory, and procoagulant vascular surface.

endothelial cell CL:0000115

Downstream

Complement activation Endothelial and complement activation coexist and may amplify one another; the direction is not fixed.

Arterial and venous thrombosis Activated endothelium promotes coagulation and vascular occlusion.

Livedo Reticularis Cutaneous vascular involvement in APS can manifest as livedo reticularis.

Livedo racemosa Cutaneous vascular involvement in APS can manifest as livedo racemosa.

Cardiac valve thickening or vegetation APS endothelial and thromboinflammatory injury can involve cardiac valves.

Show evidence (1 reference)

PMID:20822807 SUPPORT Human Clinical

"Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2."

This review supports endothelial activation as a central APS mechanism.

Monocyte tissue factor induction

Activated monocytes upregulate tissue factor and intensify thrombin generation.

monocyte CL:0000576

Downstream

Arterial and venous thrombosis Monocyte-derived tissue factor accelerates coagulation and promotes thrombus formation.

Show evidence (1 reference)

PMID:20822807 SUPPORT Human Clinical

"Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2."

This review supports monocyte activation with tissue factor overproduction as a core APS mechanism.

Platelet activation

Platelets exposed to aPL signaling become activated and generate thromboxane-dependent prothrombotic amplification.

platelet CL:0000233

platelet activation GO:0030168

Downstream

Arterial and venous thrombosis Activated platelets reinforce thrombus growth and stabilize vascular occlusion.

Thrombocytopenia Platelet involvement in APS is associated with thrombocytopenia.

Show evidence (2 references)

PMID:20822807 SUPPORT Human Clinical

"Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2."

This review supports platelet activation as a discrete prothrombotic mechanism in APS.

PMID:33878780 SUPPORT Human Clinical

"aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation."

This confirms platelet activation as part of a broader APS prothrombotic program.

Complement activation

Complement activation is a thromboinflammatory and placental-injury amplifier supported most strongly by experimental models and selected human biomarker or tissue studies; its contribution varies across APS phenotypes.

complement activation GO:0006956

Downstream

Coagulation and fibrinolytic imbalance Complement activation and abnormal hemostasis can reinforce one another, but their ordering is context dependent.

Placental immune injury Complement deposition at the maternal-fetal interface promotes placental inflammation and perfusion failure.

Show evidence (1 reference)

PMID:20822807 SUPPORT Other

"Complement activation might have a central pathogenetic role."

This review identifies complement as a core amplifier of APS pathogenesis.

Coagulation and fibrinolytic imbalance

Increased tissue-factor/thrombin-generating activity and impaired fibrin clearance shift hemostasis toward formation and persistence of thrombi.

blood coagulation GO:0007596 fibrinolysis GO:0042730

Downstream

Arterial and venous thrombosis Failure to lyse fibrin-rich clots contributes to recurrent thrombosis in arteries, veins, and microvessels.

Show evidence (1 reference)

PMID:33878780 SUPPORT Other

"Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations."

This supports impaired fibrinolysis as one component of the APS prothrombotic state.

Trigger-dependent thromboinflammatory amplification

Persistent aPL create susceptibility, but overt thrombosis is often intermittent. Infection, inflammation, vascular injury, surgery, pregnancy, or interruption of anticoagulation can supply an additional trigger; this two-hit model is useful but is not universal, especially for obstetric APS.

Downstream

Arterial and venous thrombosis A second inflammatory or vascular insult can amplify endothelial, cellular, complement, and coagulation pathways enough to precipitate an occlusive event.

Catastrophic microvascular thrombosis Infection, surgery, trauma, anticoagulation interruption, and malignancy often precede CAPS, but temporal association does not establish that one trigger is necessary or sufficient.

Show evidence (1 reference)

PMID:29867951 SUPPORT Model Organism

"infusion of anti-PL antibodies alone into the experimental animal models does not result in spontaneous thrombotic complications, thus suggesting the requirement for priming with a small vascular injury or injection of a low dose of LPS."

This gives experimental support for an additional-trigger requirement in thrombosis models.

Arterial and venous thrombosis

Objectively documented venous or arterial thrombosis is a core clinical APS manifestation; competing thrombotic risks affect attribution and classification weight. Small-vessel disease is represented separately by suspected or established microvascular manifestations and by catastrophic APS.

Downstream

Organ ischemia and damage accrual Vascular occlusion reduces tissue perfusion and causes cumulative neurologic, renal, pulmonary, and other organ injury.

Deep Vein Thrombosis APS venous thrombosis commonly includes deep vein thrombosis.

Pulmonary Embolism APS venous thrombosis can manifest as pulmonary embolism.

Ischemic stroke APS arterial thrombosis can cause ischemic stroke.

Transient ischemic attack APS arterial thrombosis can produce transient cerebral ischemia.

Arterial thrombosis APS procoagulant signaling manifests as arterial thrombosis.

Venous thrombosis APS procoagulant signaling manifests as venous thrombosis.

Show evidence (2 references)

PMID:20822807 SUPPORT Human Clinical

"The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency."

This review defines recurrent venous, arterial, and small-vessel thrombosis as a core APS event.

PMID:24321419 SUPPORT Human Clinical

"Antiphospholipid syndrome (APS) is associated with the risk of both arterial and venous thrombosis."

This provides independent support that APS drives both arterial and venous thrombotic events.

Placental immune injury

At the maternal-fetal interface, aPL can perturb trophoblast function, complement regulation, inflammatory signaling, and placental perfusion. Placental thrombosis can occur but is not a universal explanation for pregnancy loss.

trophoblast cell CL:0000351

placenta UBERON:0001987

Downstream

Pregnancy morbidity Placental dysfunction leads to miscarriage, preeclampsia, fetal growth restriction, and preterm delivery.

Show evidence (2 references)

PMID:19665761 SUPPORT Other

"Recent clinical and experimental observations suggest that the pathophysiology of pregnancy failure in patients with APS may involve inflammation at the maternal-fetal interface and disruption of normal trophoblast function and survival, rather than a pro-thrombotic event."

This supports placental inflammation and trophoblast dysfunction as a distinct APS mechanism.

PMID:19557318 SUPPORT Other

"It provides a non-invasive method for the study of uteroplacental blood flow, being able to detect a condition of impaired placental perfusion, due to the presence of circulating antiphospholipid antibodies (aPL)."

This supports impaired perfusion as one component of obstetric APS, not a universal lesion.

Pregnancy morbidity

The obstetric APS spectrum includes recurrent early pregnancy loss, fetal death, and delivery before 34 weeks because of severe preeclampsia or placental insufficiency. Other pregnancy complications may be associated but are not automatically APS-defining.

Downstream

Miscarriage Obstetric APS can present with recurrent otherwise unexplained early pregnancy loss.

Stillbirth Obstetric APS can present with otherwise unexplained fetal death.

Preterm Birth Classification focuses on delivery before 34 weeks when caused by severe preeclampsia or placental insufficiency, rather than any preterm birth.

Preeclampsia Obstetric APS and placental insufficiency can manifest as preeclampsia.

Intrauterine growth retardation Placental insufficiency in obstetric APS can restrict fetal growth.

Show evidence (2 references)

PMID:20822807 SUPPORT Other

"The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency."

This supports pregnancy loss and preterm delivery as key downstream obstetric outcomes of APS.

PMID:19557318 SUPPORT Other

"In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency."

This supports the broader set of placental-insufficiency phenotypes that define obstetric APS.

Organ ischemia and damage accrual

Recurrent thrombotic occlusion causes cumulative injury across the brain, kidneys, lungs, and other organs.

brain UBERON:0000955 kidneys UBERON:0002113 lungs UBERON:0002048

Show evidence (3 references)

PMID:22247356 SUPPORT Human Clinical

"After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died"

This cohort demonstrates cumulative damage accrual in APS over time.

PMID:27198137 SUPPORT Human Clinical

"APSN is a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries, recanalizing thrombi in arteries and arterioles, and focal atrophy"

This supports kidney injury as a representative organ-damage consequence of APS vaso-occlusion.

PMID:38368768 SUPPORT Human Clinical

"APS patients had a higher frequency of damage accrual. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual."

This confirms that recurrent vascular injury in APS produces long-term damage accrual.

Catastrophic microvascular thrombosis

Catastrophic APS is the acute multiorgan extreme of APS, with rapidly developing large- and small-vessel thrombosis and frequent thrombotic microangiopathy; it is not simply a higher count of prior macrovascular events.

brain UBERON:0000955 kidneys UBERON:0002113 lungs UBERON:0002048

Show evidence (2 references)

PMID:26753212 SUPPORT Other

"Catastrophic antiphospholipid syndrome is the most dangerous form of the antiphospholipid syndrome, which is characterized by rapid onset of thrombosis in small vessels of many organs and intravascular coagulation, thrombocytopenia and hemolytic anemia."

This defines CAPS as widespread small-vessel thrombosis with hematologic complications.

PMID:26753212 SUPPORT Other

"The syndrome develops over a short period of time with acute multi-organ failure, including kidney, respiratory, cardiovascular, central nervous system and adrenal glands, often associated with disseminated thrombotic microangiopathy."

This supports acute multiorgan failure from disseminated microvascular thrombosis as the most severe APS mechanistic outcome.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 2

Deep Vein Thrombosis Deep venous thrombosis HP:0002625

An objectively documented deep venous thrombosis can satisfy a clinical APS domain; provoking and competing risks affect attribution and classification weight, and the event does not establish APS without the aPL context.

Show evidence (2 references)

PMID:36575066 SUPPORT Human Clinical

"Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome."

The reference mentions that venous thromboembolism, which includes deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome (APS).

PMID:37640450 SUPPORT Human Clinical

"Includes (but is not limited to) pulmonary embolism, deep vein thrombosis of the legs/arms, splanchnic thrombosis, renal vein thrombosis, cerebral venous thrombosis, and retinal vein thrombosis/occlusion."

The current classification definition explicitly includes deep-vein thrombosis within macrovascular VTE.

Thrombocytopenia Thrombocytopenia HP:0001873

Usually mild-to-moderate. It was traditionally considered a non-criteria manifestation but is a weighted hematologic domain in the 2023 ACR/EULAR research-classification system; it is not specific for APS. Prevalence varies substantially with platelet threshold, cohort, and CAPS status, so no universal frequency is assigned.

Show evidence (4 references)

PMID:35536236 SUPPORT Human Clinical

"Our cohort included 74 (33.94%) patients with thrombocytopenia and 144 patients with a continuous normal platelet count."

This quantifies thrombocytopenia in one prospective primary-APS cohort without generalizing the rate.

PMID:18417261 SUPPORT Human Clinical

"Thrombocytopenia is frequently found in APS patients, its incidence has ranged from 22-42% in different series"

This review explicitly documents between-series variation.

PMID:29316193 SUPPORT Human Clinical

"Prevalence of thrombocytopenia was 6% and 100% in patients who developed the catastrophic form."

This selected triple-positive cohort demonstrates strong dependence on CAPS status and cohort definition.

+ 1 more reference

Cardiovascular 4

Cardiac valve thickening or vegetation Abnormal heart valve morphology HP:0001654

Valve thickening and sterile vegetation are nonthrombotic clinical-domain manifestations in the 2023 classification system; infective endocarditis and other valve disorders must be excluded. Reported prevalence varies with cohort and echocardiographic method, so no universal frequency is assigned.

Show evidence (3 references)

PMID:17916990 SUPPORT Human Clinical

"Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic."

A high prevalence reported with transesophageal echocardiography illustrates sensitivity to ascertainment method.

PMID:23456852 SUPPORT Human Clinical

"Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %."

The lower prevalence estimate in this review underscores cohort and method dependence.

PMID:37640450 SUPPORT Human Clinical

"clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic)"

This confirms cardiac-valve findings as a current classification domain.

Livedo Reticularis Livedo reticularis HP:0033505

Livedo reticularis is reported in APS but is nonspecific. The 2023 microvascular classification domain distinguishes persistent, irregular livedo racemosa from uniform, reversible livedo reticularis and does not score the latter.

Show evidence (1 reference)

PMID:26223086 SUPPORT Other

"Livedo reticularis is a common cutaneous manifestation of APS and may be a prognostic marker of more severe disease."

This reference states that livedo reticularis is a common cutaneous manifestation of APS, supporting its categorization as a dermatologic manifestation.

Pulmonary Embolism Pulmonary embolism HP:0002204

Pulmonary embolism is a qualifying macrovascular venous thromboembolism when objectively confirmed. Competing risks affect attribution and classification weight, and APS still requires the persistent aPL context.

Show evidence (2 references)

PMID:17165009 SUPPORT Human Clinical

"A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease)."

This review explicitly lists pulmonary embolism among the vaso-occlusive manifestations of APS.

PMID:23073594 SUPPORT Human Clinical

"Deep vein thrombosis of lower extremity (37.7%) and cerebral infarction (24.59%) were the most common thrombosis events, and then pulmonary embolism, thrombotic microangiopathy and renal artery thrombosis were also common in APS patients."

This cohort study identifies pulmonary embolism as a common thrombotic manifestation in APS patients.

Ischemic stroke Ischemic stroke HP:0002140

Show evidence (2 references)

PMID:24741580 SUPPORT Other

"Typically, neurological manifestations of APS include thrombosis of cerebral vessels leading to stroke"

This supports cerebral arterial thrombosis as the mechanism of ischemic stroke in APS.

ORPHA:80 SUPPORT Other

"HP:0002140 | Ischemic stroke | Frequent (79-30%)"

Orphanet records ischemic stroke as an APS phenotype; the source-specific frequency is not generalized.

Nervous System 1

Migraine Headaches Migraine HP:0002076

Migraine is a reported non-criteria association and is common in the general population. It should not be attributed to APS without evaluating more likely causes and does not itself establish thrombotic APS.

Show evidence (1 reference)

PMID:27423434 SUPPORT Other

"Migraine is the most commonly reported type of headache in APS/aPL-positive patients."

The literature indicates that migraine headaches are frequently reported in patients with Antiphospholipid Syndrome (APS), supporting the statement that they are an occasional neurological manifestation.

Prenatal and Birth 1

Preterm Birth Premature birth HP:0001622

The defining obstetric context is delivery before 34 weeks because of severe preeclampsia or placental insufficiency; preterm birth from another cause is not automatically attributable to APS.

Show evidence (3 references)

PMID:26815583 SUPPORT Other

"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"

The reference lists premature birth (preterm birth) as a form of obstetric morbidity associated with APS, supporting its categorization as a pregnancy-related phenotype.

PMID:34280554 SUPPORT Other

"Patients with lupus anticoagulant positivity had an increased risk of preeclampsia (OR 2.10, p = 0.02, I2 = 48%), SGA (OR 1.78, p < 0.01, I2 = 0%) and preterm birth (OR 3.56, p = 0.01, I2 = 48%)"

The meta-analysis found that APS patients, especially those with lupus anticoagulant positivity, have an increased risk of preterm birth, supporting the statement that APS phenotypes include pregnancy-related complications such as preterm birth.

PMID:37640450 SUPPORT Human Clinical

"Preeclampsia with severe features OR placental insufficiency with severe features (<34 weeks) with or without fetal death"

This supplies the severe-feature and gestational boundary rather than treating every preterm birth as APS-defining.

Growth 1

Intrauterine growth retardation Intrauterine growth retardation HP:0001511

Show evidence (2 references)

ORPHA:80 SUPPORT Other

"HP:0001511 | Intrauterine growth retardation | Very frequent (99-80%)"

Orphanet records fetal growth restriction as an APS-associated pregnancy phenotype, but its source-specific frequency is not generalized here.

PMID:37640450 SUPPORT Human Clinical

"Intrauterine fetal growth restriction defined as biometry indicating estimated fetal weight of less than the 10th percentile"

This grounds fetal growth restriction within the current severe placental-insufficiency definition; additional severe features are still required.

Other 13

Miscarriage

The 2023 low-weight obstetric item requires three or more consecutive, otherwise unexplained prefetal losses before 10 weeks and/or early fetal deaths from 10 through 15 weeks 6 days. It does not by itself reach the three-point clinical classification threshold; a single sporadic early miscarriage is not sufficient to establish APS.

Show evidence (2 references)

PMID:26815583 SUPPORT Other

"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"

This directly identifies recurrent first-trimester loss as obstetric APS morbidity.

PMID:37640450 SUPPORT Human Clinical

"occurrence of 3 or more consecutive prefetal deaths (at<10 weeks) and/or early fetal deaths (at 10–16 weeks)"

This supplies the current recurrence and gestational boundaries for the low-weight obstetric item.

Stillbirth

The 2023 obstetric domain includes otherwise unexplained fetal death from 10 weeks through 34 weeks, with gestation and recurrence affecting weight. The The Stillbirth label captures only part of that broader fetal-death domain; alternative fetal, placental, and maternal causes must be assessed.

Show evidence (2 references)

PMID:26815583 SUPPORT Other

"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"

This directly identifies stillbirth and intrauterine death in obstetric APS.

PMID:37640450 SUPPORT Human Clinical

"or one or more fetal deaths (at≥16 weeks to<34 weeks) alone"

This supplies the current later-fetal-death gestational boundary.

Preeclampsia preeclampsia MONDO:0005081

The APS classification manifestation is severe preeclampsia leading to delivery before 34 weeks, not preeclampsia of any severity or gestation.

Show evidence (3 references)

PMID:26815583 SUPPORT Other

"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"

This supports preeclampsia within obstetric APS without assigning a universal frequency.

PMID:32413497 SUPPORT Other

"Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia)."

This specifically identifies severe preeclampsia as a major obstetric presentation.

PMID:37640450 SUPPORT Human Clinical

"Preeclampsia with severe features OR placental insufficiency with severe features (<34 weeks) with or without fetal death"

This directly supports the severe-feature and less-than-34-week boundary.

Transient ischemic attack Transient ischemic attack HP:0002326

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0002326 | Transient ischemic attack | Frequent (79-30%)"

Orphanet records TIA as an associated APS phenotype without resolving its diagnostic specificity.

Antiphospholipid antibody positivity Antiphospholipid antibody positivity HP:0003613

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0003613 | Antiphospholipid antibody positivity | Frequent (79-30%)"

Orphanet records aPL positivity as an APS laboratory phenotype; no universal frequency is inferred.

Arterial thrombosis Arterial thrombosis HP:0004420

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0004420 | Arterial thrombosis | Frequent (79-30%)"

Orphanet records arterial thrombosis as an APS phenotype without establishing a universal rate.

Venous thrombosis Venous thrombosis HP:0004936

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0004936 | Venous thrombosis | Frequent (79-30%)"

Orphanet records venous thrombosis as an APS phenotype without establishing a universal rate.

Anticardiolipin IgG antibody positivity Anticardiolipin IgG antibody positivity HP:0020136

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0020136 | Anticardiolipin IgG antibody positivity | Frequent (79-30%)"

Orphanet records anticardiolipin IgG positivity as an APS laboratory phenotype.

Anticardiolipin IgM antibody positivity Anticardiolipin IgM antibody positivity HP:0020137

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0020137 | Anticardiolipin IgM antibody positivity | Frequent (79-30%)"

Orphanet records anticardiolipin IgM positivity as an APS laboratory phenotype.

Lupus anticoagulant Lupus anticoagulant HP:0025343

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0025343 | Lupus anticoagulant | Frequent (79-30%)"

Orphanet records lupus anticoagulant as an APS laboratory phenotype.

Anti-beta 2 glycoprotein I antibody positivity Anti-beta 2 glycoprotein I antibody positivity HP:0032376

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0032376 | Anti-beta 2 glycoprotein I antibody positivity | Frequent (79-30%)"

Orphanet records anti-beta2GPI positivity as an APS laboratory phenotype.

Livedo racemosa Livedo racemosa HP:0033260

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0033260 | Livedo racemosa | Frequent (79-30%)"

Orphanet records livedo racemosa as an APS-associated cutaneous phenotype.

Anti-beta-2-Glycoprotein I IgG antibody positivity Anti-beta-2-Glycoprotein I IgG antibody positivity HP:0034156

Show evidence (1 reference)

ORPHA:80 SUPPORT Other

"HP:0034156 | Anti-beta-2-Glycoprotein I IgG antibody positivity | Frequent (79-30%)"

Orphanet records IgG anti-beta2GPI positivity as an APS laboratory phenotype.

🧬

Genetic Associations

HLA class II regulatory locus near HLA-DRA (Genome-wide-significant common-variant susceptibility locus)

relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:38973605 SUPPORT Human Clinical

"We revealed genetic associations with PAPS in a regulatory locus within the HLA class II region near HLA-DRA and in STAT1-STAT4 with a genome-wide level of significance; 34 additional suggestive genetic susceptibility loci for PAPS were also identified."

The primary GWAS directly supports a genome-wide-significant HLA class II region susceptibility signal while leaving the causal gene unresolved.

STAT1-STAT4 susceptibility locus (Genome-wide-significant common-variant susceptibility locus)

relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:38973605 SUPPORT Human Clinical

The primary GWAS directly supports a genome-wide-significant STAT1-STAT4 region susceptibility signal while leaving the causal element unresolved.

💊

Medical Actions

Long-term warfarin anticoagulation

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: warfarin CHEBI:10033

Vitamin K antagonist therapy is standard secondary prevention for thrombotic APS. For a first unprovoked venous event, the usual target INR is 2-3; after an arterial event, INR 2-3 versus 3-4 is individualized to thrombosis and bleeding risk. Recurrent thrombosis despite adequate therapy prompts adherence/INR review and selected escalation rather than assuming universal treatment failure.

Mechanism Target:

INHIBITS Coagulation and fibrinolytic imbalance — Vitamin K antagonism reduces thrombin generation and recurrence risk; it does not remove aPL or normalize upstream autoimmunity.

Show evidence (1 reference)

PMID:31092409 PARTIAL Other

"Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3."

The recommendation supports targeting the coagulation arm, while the molecular treatment effect is a pharmacologic inference.

Target Phenotypes: Venous thrombosis HP:0004936 Arterial thrombosis HP:0004420

Show evidence (3 references)

PMID:31092409 SUPPORT Other

"Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3."

This directly supports long-term VKA therapy and the usual venous target INR.

PMID:31092409 SUPPORT Other

"In patients with APS with first arterial thrombosis, treatment with VKA with INR 2-3 or INR 3-4 is recommended, considering the individual's bleeding/thrombosis risk."

This supports individualized VKA intensity after arterial thrombosis.

PMID:36328154 SUPPORT Human Clinical

"Patients with thrombotic antiphospholipid syndrome randomized to DOACs compared with VKAs appear to have increased risk for arterial thrombosis."

Randomized-trial meta-analysis argues against routine DOAC substitution, especially when arterial risk is relevant.

Heparin plus low-dose aspirin in pregnancy

Category: Therapeutic Action: aspirin therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: heparin CHEBI:28304 aspirin CHEBI:15365

Low-dose aspirin plus prophylactic-dose heparin is recommended during pregnancy for women with prior obstetric APS. Dosing and peripartum timing require individualized obstetric and thrombosis planning; this statement does not extend the regimen to every aPL-positive pregnancy.

Mechanism Target:

INHIBITS Platelet activation — Low-dose aspirin inhibits platelet thromboxane signaling within the obstetric regimen.

Show evidence (1 reference)

PMID:31092409 PARTIAL Other

"In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended."

The clinical recommendation supports the regimen; platelet-pathway attribution follows aspirin pharmacology.

INHIBITS Coagulation and fibrinolytic imbalance — Heparin suppresses coagulation within the combined regimen and may have additional placental effects.

Show evidence (1 reference)

PMID:31092409 PARTIAL Other

"In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended."

The clinical recommendation supports heparin use; this does not prove that anticoagulation is the sole placental mechanism.

Target Phenotypes: Miscarriage Stillbirth Preterm Birth HP:0001622

Show evidence (1 reference)

PMID:31092409 SUPPORT Other

"In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended."

This directly supports the standard obstetric regimen and its population boundary.

Adjunct hydroxychloroquine

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: hydroxychloroquine CHEBI:5801

Hydroxychloroquine may be considered as an add-on when pregnancy complications recur despite aspirin plus heparin. It is not a substitute for anticoagulation in thrombotic APS, and evidence for APS-specific benefit remains limited.

Mechanism Target:

INHIBITS Placental immune injury — Hydroxychloroquine is used as an immunomodulatory adjunct, but the clinical recommendation does not establish one placental molecular target.

Show evidence (1 reference)

PMID:31092409 PARTIAL Other

"In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered."

This supports use as an obstetric add-on while leaving the specific placental mechanism uncertain.

Target Phenotypes: Miscarriage

Show evidence (1 reference)

PMID:31092409 PARTIAL Other

The guideline frames hydroxychloroquine as an option for recurrence, not routine first-line monotherapy.

Catastrophic APS combination therapy

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: heparin CHEBI:28304 glucocorticoid CHEBI:24261

Suspected catastrophic APS is a medical emergency. Standard combination treatment uses therapeutic intravenous heparin plus glucocorticoids and plasma exchange and/or IVIG while the precipitating factor and organ failure are treated. Diagnostic testing should not delay therapy when suspicion is high.

Mechanism Target:

INHIBITS Coagulation and fibrinolytic imbalance — Intravenous heparin suppresses the coagulation arm of catastrophic thromboinflammation.

Show evidence (1 reference)

PMID:39644034 PARTIAL Other

"Management of CAPS requires "triple therapy" with glucocorticoids, intravenous heparin, therapeutic plasma exchange, and/or intravenous immunoglobulin."

This supports heparin as a required component; the target-mechanism statement reflects anticoagulant pharmacology.

INHIBITS Complement activation — Plasma exchange, IVIG, and glucocorticoids broadly modulate antibody-driven inflammation; their benefit is not proof that one complement step dominates every CAPS case.

Show evidence (1 reference)

PMID:27886797 PARTIAL Other

"from the experimental or basic point of view, there is only indirect evidence to advocate the use of these immunomodulatory therapies (GC, PE, and IVIG) in CAPS."

This explicitly limits mechanistic confidence for the immunomodulatory components.

Show evidence (1 reference)

PMID:39644034 SUPPORT Other

"Management of CAPS requires "triple therapy" with glucocorticoids, intravenous heparin, therapeutic plasma exchange, and/or intravenous immunoglobulin."

This directly supports current combination management.

Rituximab or eculizumab for refractory catastrophic APS

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: rituximab NCIT:C1702 eculizumab NCIT:C48386

B-cell depletion with rituximab or C5 inhibition with eculizumab may be used in selected refractory CAPS, but support is based on poor-quality evidence rather than randomized trials. These agents are escalation options, not routine substitutes for combination therapy.

Mechanism Target:

INHIBITS Autoantibody generation against beta2GPI and phospholipid complexes — Rituximab depletes CD20-positive B cells upstream of ongoing autoantibody production.

Show evidence (1 reference)

PMID:27886797 PARTIAL Other

"The first blocks CD20, a surface protein expressed on the cytoplasmic membrane of B cells, and decreases the generation of pathogenic autoantibodies such as antiphospholipid (aPL) antibodies."

This supports the proposed B-cell/aPL target, but clinical outcome evidence remains limited.

INHIBITS Complement activation — Eculizumab blocks C5 cleavage and terminal-complement-complex generation.

Show evidence (1 reference)

PMID:27886797 PARTIAL Other

"The second binds with high affinity to C5 complement protein, inhibiting its cleavage and thus preventing the generation of C5b-C9 complex."

This directly supports the molecular target, while clinical efficacy evidence is limited to reports.

Show evidence (1 reference)

PMID:39644034 PARTIAL Other

"Treatment for refractory disease is based on poor-quality evidence but includes anti-CD20 (rituximab) or anticomplement (eculizumab) monoclonal antibodies and other immunosuppressant agents, either alone or in combination."

This supports selected refractory use and explicitly records the evidence limitation.

🔬

Biochemical Markers

Persistent criterion antiphospholipid-antibody profile (Positive)

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"patients with persistent antiphospholipid antibodies (aPL)"

Persistent aPL are part of the disease definition, but require an associated clinical manifestation.

Lupus Anticoagulant (Positive)

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"lupus anticoagulant functional coagulation assays"

Lupus anticoagulant is represented correctly as a functional assay domain and requires persistence for full classification weight.

Anti-Cardiolipin Antibodies (Positive)

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β2-glycoprotein I antibodies"

This defines anticardiolipin IgG/IgM as one of the two solid-phase criterion assay families.

Beta-2 Glycoprotein I Antibodies (Positive)

Show evidence (1 reference)

PMID:37640450 SUPPORT Human Clinical

"solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β2-glycoprotein I antibodies"

This defines anti-beta2GPI IgG/IgM as a criterion solid-phase assay family.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Antiphospholipid Syndrome:

Thrombotic thrombocytopenic purpura Not Yet Curated MONDO:0018896

Overlapping Features Thrombotic thrombocytopenic purpura can closely mimic catastrophic APS through thrombocytopenia, microangiopathic hemolysis, neurologic injury, renal dysfunction, and multiorgan ischemia.

Distinguishing Features

Undetectable ADAMTS13 activity strongly favors thrombotic thrombocytopenic purpura.
Rapid multisite thrombosis and organ dysfunction in a patient with a qualifying APS clinical and persistent laboratory context support CAPS; aPL positivity alone and empiric anticoagulation do not distinguish CAPS from TTP.

Show evidence (2 references)

PMID:10483019 SUPPORT Human Clinical

"The differential diagnosis of CAPS includes thrombotic thrombocytopenic purpura (TTP) and this distinction may be difficult, but essential, for appropriate therapy."

This directly identifies TTP as a core differential diagnosis for catastrophic APS.

PMID:25879992 SUPPORT Other

"The definitive marker for thrombotic thrombocytopenic purpura is undetectable ADAMTS 13 activity."

This supports ADAMTS13 deficiency as a key laboratory feature distinguishing TTP from APS-related thrombotic microangiopathy.

HELLP syndrome Not Yet Curated MONDO:0008585

Overlapping Features HELLP syndrome overlaps with obstetric APS and catastrophic APS through thrombocytopenia, hemolysis, liver injury, and severe pregnancy-associated maternal morbidity.

Distinguishing Features

A pregnancy-specific pre-eclampsia context with hemolysis, elevated liver enzymes, and low platelet count favors HELLP syndrome.
Neurologic involvement, dialysis requirement, or absent disseminated intravascular coagulation raise concern for thrombotic microangiopathy or APS mimics rather than isolated HELLP.

Show evidence (2 references)

PMID:25879992 SUPPORT Other

"Pre-eclampsia complicated by severe HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome is a multi-organ disease, and can be difficult to differentiate from thrombotic microangiopathy (appearing as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome), acute..."

This review explicitly names antiphospholipid syndrome among the major disorders that can be confused with severe HELLP syndrome.

PMID:25879992 SUPPORT Other

"Relevant identifiers to establish the most accurate diagnosis include the frequency of each disease and anamnestic data. Frank hemolysis, need for dialysis, neurological involvement and absence of disseminated intravascular coagulation are indicative of thrombotic microangiopathy."

This supports specific distinguishing features that help separate HELLP syndrome from APS-related thrombotic microangiopathy.

Systemic lupus erythematosus MONDO:0007915

Overlapping Features Systemic lupus erythematosus frequently co-occurs with APS and may be mistaken for primary APS when antiphospholipid antibodies are present alongside broader systemic autoimmune findings.

Distinguishing Features

SLE-specific nephropathy, arthritis, cutaneous or neurologic lupus manifestations, anti-dsDNA, anti-Sm, or high-titer ANA favor systemic lupus erythematosus.
Strictly defined primary APS can satisfy some lupus classification items without progressing to clinical SLE on long-term follow-up.

Show evidence (2 references)

PMID:30005859 SUPPORT Human Clinical

"We successively excluded patients with (1) at least one "SLE-specific" manifestation (biopsy-proven SLE nephropathy, arthritis, cutaneous, or neurologic SLE manifestations, pericarditis, autoimmune haemolytic anaemia, oral and nasal ulcers, non-scarring alopecia, anti-dsDNA, and anti-Sm..."

This cohort analysis outlines the clinical and serologic features used to distinguish SLE from primary APS.

PMID:30005859 SUPPORT Human Clinical

"Because 28% of our patients with longstanding and strictly defined PAPS could be mistakenly classified as SLE, they were at risk of deleterious therapeutic management."

This directly supports SLE as an important diagnostic pitfall and differential diagnosis for primary APS.

📊

Related Datasets

A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome DOI:10.1002/art.42947

Large genome-wide association study resource for primary APS, used to identify susceptibility loci and compare the genetic architecture of APS with other immune-mediated diseases.

human GWAS n=5485

Conditions: primary antiphospholipid syndrome immune-mediated disease genetic comparison

PMID:38973605

Show evidence (1 reference)

PMID:38973605 SUPPORT Human Clinical

"METHODS: We performed a genome-wide association study comprising 5,485 individuals (482 affected individuals) of European ancestry."

This supports the cohort size and GWAS design of a major primary APS genetics dataset.

Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus DOI:10.1136/annrheumdis-2013-204600

Human monocyte microarray dataset comparing APS, APS plus SLE, SLE, and healthy donors to define inflammatory, atherosclerotic, and prothrombotic transcriptional programs.

human MICROARRAY n=190

peripheral blood monocytes CL:0000576

Conditions: primary antiphospholipid syndrome antiphospholipid syndrome associated with systemic lupus erythematosus systemic lupus erythematosus healthy controls

PMID:24618261

Show evidence (1 reference)

PMID:24618261 SUPPORT Human Clinical

"METHODS: 129 patients (42 APS, 31 APS plus SLE and 56 SLE) and 61 healthy donors were included. Microarray expression profiling was performed in monocytes."

This supports a disease-relevant monocyte transcriptomic dataset spanning APS and overlapping autoimmune comparator groups.

Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome DOI:10.3389/fimmu.2021.702425

Urine proteomics dataset distinguishing primary thrombotic APS from primary obstetric APS using iTRAQ and liquid chromatography-tandem mass spectrometry.

human PROTEOMICS n=39

urine sample

Conditions: primary thrombotic antiphospholipid syndrome primary obstetric antiphospholipid syndrome healthy controls

PMID:34489952

Show evidence (1 reference)

PMID:34489952 SUPPORT Human Clinical

"Urine samples from 15 patients with TAPS, 9 patients with OAPS, and 15 healthy controls (HCs) were collected and analyzed using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis to identify differentially..."

This supports a human APS proteomics dataset spanning thrombotic and obstetric primary APS subgroups.

{ }

Source YAML

click to show

name: Antiphospholipid Syndrome
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-07-24T02:07:22Z'
synonyms:
- APS
- antiphospholipid antibody syndrome
- Hughes syndrome
description: >-
  An acquired systemic autoimmune thrombophilia in which persistent,
  clinically relevant antiphospholipid antibodies occur in association with
  arterial, venous, or microvascular thrombosis and/or defined pregnancy
  morbidity. Competing causes affect clinical attribution; antibody positivity
  without an associated manifestation is an aPL-carrier state, not
  "asymptomatic APS."
definitions:
- name: 2023 ACR/EULAR APS classification criteria
  definition_type: OTHER
  description: >-
    A weighted research-classification system designed for high specificity.
    It is not a stand-alone diagnostic rule and should not override clinical
    judgment or exclude otherwise clinically diagnosed patients.
  scope: Research classification of people with suspected APS
  criteria_sets:
  - name: Entry criterion
    description: >-
      At least one positive aPL test must occur within three years of an
      aPL-associated clinical criterion.
    minimum_required: 1
    evidence:
    - reference: PMID:37640450
      reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion
      explanation: This is the temporal entry gate for applying the weighted criteria.
  - name: Weighted clinical and laboratory domains
    description: >-
      After the entry criterion, classification requires at least three points
      from clinical domains and at least three points from laboratory domains.
      Clinical domains are macrovascular venous, macrovascular arterial,
      microvascular, obstetric, cardiac-valve, and hematologic; laboratory
      domains are lupus-anticoagulant functional assays and solid-phase aCL or
      anti-beta2GPI assays.
    evidence:
    - reference: PMID:37640450
      reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS.
      explanation: This gives the two independent score thresholds.
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR.
    explanation: The stated purpose confines this tool to classification for research rather than clinical diagnosis.
- name: 2006 revised Sapporo (Sydney) classification criteria
  definition_type: OTHER
  description: >-
    The historical research criteria require at least one qualifying thrombosis
    or pregnancy-morbidity criterion and at least one qualifying laboratory
    criterion, with persistent aPL demonstrated on two tests at least 12 weeks
    apart. They remain clinically informative but are classification criteria.
  scope: Historical research classification of thrombotic or obstetric APS
  criteria_sets:
  - name: Clinical criterion
    description: >-
      At least one objectively documented vascular thrombosis or qualifying
      pregnancy-morbidity criterion is required.
    minimum_required: 1
    evidence:
    - reference: PMID:24461539
      reference_title: Diagnosis and classification of the antiphospholipid syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS.
      explanation: This states the required clinical arm and distinguishes classification from diagnosis.
  - name: Persistent laboratory criterion
    description: >-
      At least one qualifying lupus anticoagulant, IgG/IgM anticardiolipin, or
      IgG/IgM anti-beta2GPI result is required, with positivity demonstrated on
      two tests at least 12 weeks apart.
    minimum_required: 1
    evidence:
    - reference: PMID:24461539
      reference_title: Diagnosis and classification of the antiphospholipid syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS.
      explanation: This supplies the three laboratory families and the clinical-laboratory pairing.
    - reference: PMID:37640450
      reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: the definition of aPL “persistence” (ie, 2 positive tests for aPL at least 12 weeks apart)
      explanation: This states the historical persistence interval retained in current criteria work.
  evidence:
  - reference: PMID:24461539
    reference_title: Diagnosis and classification of the antiphospholipid syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The Sapporo criteria, as they are often called, were revised at another workshop in Sydney, Australia, in 2004, during the 11th International Congress on aPL.
    explanation: This supports the historical Sydney revision represented by this definition.
category: Complex
parents:
- Autoimmune Disease
has_subtypes:
- name: Primary antiphospholipid syndrome
  description: APS occurring without another associated autoimmune disease.
  subtype_term:
    preferred_term: primary antiphospholipid syndrome
    term:
      id: MONDO:0005204
      label: primary antiphospholipid syndrome
  evidence:
  - reference: PMID:27550302
    reference_title: Kidney disease in primary anti-phospholipid antibody syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: APS can be isolated (primary APS) or associated with other autoimmune diseases.
    explanation: This supports the primary-versus-associated distinction.
- name: Secondary antiphospholipid syndrome
  description: >-
    APS occurring with another autoimmune disease, most often systemic lupus
    erythematosus; the associated disease does not remove the requirement for
    clinical APS manifestations and persistent aPL.
  subtype_term:
    preferred_term: secondary antiphospholipid syndrome
    term:
      id: MONDO:0021008
      label: secondary antiphospholipid syndrome
  evidence:
  - reference: PMID:27550302
    reference_title: Kidney disease in primary anti-phospholipid antibody syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: APS can be isolated (primary APS) or associated with other autoimmune diseases.
    explanation: This supports APS associated with another autoimmune disease.
- name: Catastrophic antiphospholipid syndrome
  description: >-
    A rare, life-threatening form with rapidly developing large- and
    small-vessel thrombosis at multiple sites and acute multiorgan dysfunction.
  subtype_term:
    preferred_term: catastrophic antiphospholipid syndrome
    term:
      id: MONDO:0018737
      label: catastrophic antiphospholipid syndrome
  evidence:
  - reference: PMID:39644034
    reference_title: "Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Catastrophic antiphospholipid syndrome (CAPS) is a rare but life-threatening form of antiphospholipid syndrome (APS) defined by the rapid onset of large and small vessel thrombosis occurring simultaneously across multiple sites, resulting in multiorgan dysfunction.
    explanation: This provides the current clinical boundary for catastrophic APS.
prevalence:
- population: Adults in Olmsted County, Minnesota, 2000-2015
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 50.0
  percentage: 0.05
  notes: >-
    Estimate from 33 incident Sydney-classified cases in a predominantly White
    US population; it should not be treated as a universal global rate.
  evidence:
  - reference: PMID:30957430
    reference_title: "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The estimated prevalence of APS was 50 (95% CI 42-58) per 100,000 population, and was similar in both sexes.
    explanation: This supports the point estimate and its cohort-specific uncertainty interval.
- population: Adults in Olmsted County, Minnesota, 2000-2015
  measure_type: ANNUAL_INCIDENCE
  rate_per_100000: 2.1
  notes: Age- and sex-adjusted annual incidence; 95% CI 1.4-2.8 per 100,000.
  evidence:
  - reference: PMID:30957430
    reference_title: "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The annual incidence of APS in adults ages ≥18 years was 2.1
    explanation: This is a population-based annual incidence estimate rather than a prevalence measure.
epidemiology:
- name: Sex distribution depends on ascertainment
  description: >-
    Population-based incidence in one US study was similar in women and men;
    female predominance in autoimmune referral cohorts should not be generalized
    to population incidence.
  factors:
  - sex
  evidence:
  - reference: PMID:30957430
    reference_title: "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Incidence rates were similar in both sexes.
    explanation: This directly supports the population-based sex boundary.
diagnosis:
- name: Clinical diagnosis integrating manifestations, persistence, and alternatives
  description: >-
    Diagnose APS clinically by integrating objectively documented thrombosis or
    characteristic pregnancy morbidity with a persistent, clinically relevant
    aPL profile, while assessing whether another cause better explains the
    event. A positive aPL test alone is not APS, and neither the 2006 nor 2023
    research-classification criteria should be used as an inflexible diagnostic
    exclusion rule.
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Classification of APS, for the identification of homogeneous research cohorts
    explanation: This explicitly identifies the criteria's research-classification purpose.
  - reference: PMID:15290736
    reference_title: "Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients with primary or secondary antiphospholipid syndrome (APS, n = 226); and (2) asymptomatic carriers of aPL (n = 178).
    explanation: The study treats aPL carriers as distinct from patients with APS.
- name: Core antiphospholipid laboratory panel
  description: >-
    Test lupus anticoagulant by functional coagulation assays and test IgG/IgM
    anticardiolipin and IgG/IgM anti-beta2GPI by solid-phase immunoassay. Lupus
    anticoagulant is an assay-defined functional phenomenon, not the name of one
    antibody species.
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β2-glycoprotein I antibodies).
    explanation: This defines the core functional and solid-phase assay families without mislabeling lupus anticoagulant as a single antibody.
- name: Confirm persistent antibody positivity
  description: >-
    Repeat a positive criterion aPL result after at least 12 weeks. Persistence
    reduces misclassification from transient aPL, including antibodies detected
    around infection; laboratory interpretation must also account for assay and
    anticoagulant-related interference.
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: '"persistent" aPL test results (at least 12 weeks apart) should be scored based on two consecutive positive lupus anticoagulant (LAC)'
    explanation: The current criteria retain consecutive testing for persistence.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the definition of aPL “persistence” (ie, 2 positive tests for aPL at least 12 weeks apart)
    explanation: This supplies the minimum repeat-testing interval.
pathophysiology:
- name: CD4+ T cell dysregulation and autoreactive B cell licensing
  description: >-
    Altered helper, regulatory, and follicular CD4+ T-cell profiles are reported
    in primary APS, but whether they initiate persistent aPL production or arise
    after established autoimmunity remains unresolved.
  cell_types:
  - preferred_term: helper T cell
    term:
      id: CL:0000912
      label: helper T cell
  - preferred_term: regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  - preferred_term: T follicular helper cell
    term:
      id: CL:0002038
      label: T follicular helper cell
  downstream:
  - target: Autoantibody generation against beta2GPI and phospholipid complexes
    description: >-
      Autoreactive CD4+ T-cell help is a plausible contributor to aPL-specific
      B-cell responses; human observations are associative and the upstream
      trigger is unknown.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:42229606
      reference_title: "Dysregulation of helper, regulatory, and follicular CD4(+) T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy."
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: Experimental studies demonstrate that autoreactive aPL-specific CD4+ T cells are critical for initiating and maintaining aPL responses.
      explanation: Experimental studies support T-cell dependence, but do not establish the direction of causality in human APS.
  evidence:
  - reference: PMID:42229606
    reference_title: "Dysregulation of helper, regulatory, and follicular CD4(+) T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: APS is skewed toward Th1 and Th17 polarization, diminished Treg frequency or function, and a dysregulated Tfh/Tfr axis. Specifically, increased activated Tfh cells alongside reduced Tfr cells and skewing toward Tfh17-like subsets, have been linked to increased aPL titres and disease burden.
    explanation: The human associations support immune imbalance but do not show that it drives aPL production.
  - reference: PMID:42229606
    reference_title: "Dysregulation of helper, regulatory, and follicular CD4(+) T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: the cumulative data support a model in which APS involves a coordinated disruption of CD4+ T cell homeostasis, encompassing both effector and regulatory arms.
    explanation: The authors propose a coordinated-imbalance model while explicitly noting inconsistent findings.
- name: Autoantibody generation against beta2GPI and phospholipid complexes
  description: >-
    Persistent aPL responses are heterogeneous but clinically important
    reactivity is commonly directed against phospholipid-binding proteins,
    especially beta2GPI. The immune events that initiate and sustain these
    responses are incompletely established.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
  downstream:
  - target: Cell-surface beta2GPI binding
    description: Circulating aPL bind beta2GPI and phospholipid-associated targets on vascular and placental surfaces.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29867951
      reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces.
      explanation: This supports the transition from antibody generation to pathogenic beta2GPI binding on cell surfaces.
  - target: Antiphospholipid antibody positivity
    description: Autoantibody generation manifests clinically as antiphospholipid antibody positivity.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003613 | Antiphospholipid antibody positivity | Frequent (79-30%)"
      explanation: Orphanet records antiphospholipid antibody positivity as a frequent APS phenotype.
  - target: Anticardiolipin IgG antibody positivity
    description: Autoantibody generation includes anticardiolipin IgG antibodies.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0020136 | Anticardiolipin IgG antibody positivity | Frequent (79-30%)"
      explanation: Orphanet records anticardiolipin IgG antibody positivity as a frequent APS phenotype.
  - target: Anticardiolipin IgM antibody positivity
    description: Autoantibody generation includes anticardiolipin IgM antibodies.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0020137 | Anticardiolipin IgM antibody positivity | Frequent (79-30%)"
      explanation: Orphanet records anticardiolipin IgM antibody positivity as a frequent APS phenotype.
  - target: Lupus anticoagulant
    description: Autoantibody generation includes lupus anticoagulant activity detected in APS laboratory testing.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0025343 | Lupus anticoagulant | Frequent (79-30%)"
      explanation: Orphanet records lupus anticoagulant as a frequent APS phenotype.
  - target: Anti-beta 2 glycoprotein I antibody positivity
    description: Autoantibody generation includes anti-beta2 glycoprotein I antibodies.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0032376 | Anti-beta 2 glycoprotein I antibody positivity | Frequent (79-30%)"
      explanation: Orphanet records anti-beta 2 glycoprotein I antibody positivity as a frequent APS phenotype.
  - target: Anti-beta-2-Glycoprotein I IgG antibody positivity
    description: Autoantibody generation includes anti-beta2 glycoprotein I IgG antibodies.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0034156 | Anti-beta-2-Glycoprotein I IgG antibody positivity | Frequent (79-30%)"
      explanation: Orphanet records anti-beta-2-Glycoprotein I IgG antibody positivity as a frequent APS phenotype.
  evidence:
  - reference: PMID:29867951
    reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein β2 glycoprotein I (β2GPI) or that directly recognize negatively charged membrane phospholipids in a manner that may contribute to arterial or venous thrombosis.
    explanation: This review supports aPL availability as an upstream disease feature while preserving antibody heterogeneity.
  - reference: PMID:33722752
    reference_title: "B cells in primary antiphospholipid syndrome: Review and remaining challenges."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS).
    explanation: This supports the role of adaptive immune cells, especially B cells, in generating pathogenic antiphospholipid antibodies.
- name: Cell-surface beta2GPI binding
  description: >-
    Anti-beta2GPI/beta2GPI complexes can assemble along phospholipid-rich cell
    surfaces. Receptor usage and the importance of particular antibody
    specificities vary across experimental systems.
  downstream:
  - target: Innate receptor signaling
    description: Surface-bound immune complexes engage receptors such as TLR4 and trigger downstream inflammatory signaling cascades.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22055541
      reference_title: "Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: TLR4, p38 MAPK and NFκB are involved in mediating pathogenic effects of aPL on different cell types and may be potential therapeutic targets in antiphospholipid syndrome.
      explanation: This supports the edge from surface beta2GPI binding to receptor-mediated pathogenic signaling.
  - target: Placental immune injury
    description: >-
      Beta2GPI-dependent antibodies can bind trophoblast and decidual surfaces
      and perturb placental-cell function without requiring placental thrombosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - trophoblast binding and signaling
    - altered trophoblast proliferation, differentiation, and survival
    evidence:
    - reference: PMID:29867951
      reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Binding of β2GPI-dependent antibodies to human trophoblasts inhibits cell proliferation and syncitia formation, decreases production of chorionic gonadotrophin, perturbs secretion of growth factors, and induces apoptosis
      explanation: This supports a direct placental-cell branch distinct from macrovascular thrombosis.
  evidence:
  - reference: PMID:29867951
    reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces.
    explanation: This supports pathogenic antibody binding along cellular surfaces as a distinct intermediate APS event.
- name: Innate receptor signaling
  description: >-
    Experimental systems implicate TLR4, p38 MAPK, NF-kappaB, and related
    pathways after aPL-beta2GPI binding; no single receptor-signaling route has
    been established as universal across APS patients.
  downstream:
  - target: Endothelial activation
    description: Intracellular signaling induces a proadhesive and procoagulant endothelial phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports endothelial activation as a downstream consequence of pathogenic aPL signaling.
  - target: Monocyte tissue factor induction
    description: Signaling in monocytes induces tissue factor expression and amplifies coagulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports monocyte activation with tissue factor induction as a discrete prothrombotic mechanism in APS.
  - target: Platelet activation
    description: Signaling promotes platelet activation and thromboxane-driven thrombus propagation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports platelet activation as a distinct downstream consequence of aPL signaling.
  - target: Neutrophil extracellular-trap amplification
    description: >-
      Anti-beta2GPI can promote NET release, adding a neutrophil-mediated
      immunothrombotic amplifier.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29867951
      reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In vitro, neutrophils respond to incubation with anti-β2GPI antibodies by an intensified NET release
      explanation: This is direct in-vitro support; its quantitative contribution in patients remains uncertain.
  evidence:
  - reference: PMID:22055541
    reference_title: "Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Diverse experimental evidence exists implicating the activation of various different cell surface receptors and intracellular pathways by antiphospholipid antibodies (aPL).
    explanation: This review supports a distinct signaling step between antibody binding and overt thrombosis.
  - reference: PMID:22055541
    reference_title: "Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: TLR4, p38 MAPK and NFκB are involved in mediating pathogenic effects of aPL on different cell types and may be potential therapeutic targets in antiphospholipid syndrome.
    explanation: This identifies a specific innate signaling axis activated by aPL-beta2GPI complexes.
- name: Neutrophil extracellular-trap amplification
  description: >-
    APS neutrophils can release excess neutrophil extracellular traps (NETs),
    whose chromatin and granule proteins provide a candidate immunothrombotic
    scaffold. Human, in-vitro, and animal observations support this amplifier,
    but do not establish NETs as necessary in every thrombotic event.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil extracellular trap formation
    term:
      id: GO:0140645
      label: neutrophil extracellular trap formation
  downstream:
  - target: Arterial and venous thrombosis
    description: NET-derived material can amplify coagulation and thrombus growth.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - extracellular chromatin scaffold
    - platelet and coagulation-factor recruitment
    evidence:
    - reference: PMID:29867951
      reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: Neutrophil extracellular traps are important in the context of APS because APS patient neutrophils are prone to spontaneous NET release (22), and thrombi incorporate NET-derived materials (21–23, 81).
      explanation: This supports NETs as an amplifier while stopping short of a universal causal claim.
  evidence:
  - reference: PMID:29867951
    reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In animal models, inhibitors of NET release show promise in reducing thrombus formation, and mice deficient for PAD4, the enzyme that deiminates histones and promotes DNA unraveling in NETs, are resistant to pro-thrombotic stimuli
    explanation: Experimental perturbation supports a mechanistic contribution from NET formation.
- name: Endothelial activation
  description: aPL signaling converts endothelial cells into a proadhesive, inflammatory, and procoagulant vascular surface.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  downstream:
  - target: Complement activation
    description: Endothelial and complement activation coexist and may amplify one another; the direction is not fixed.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:33878780
      reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
      explanation: The source supports coupling, not a unidirectional endothelial-to-complement sequence.
  - target: Arterial and venous thrombosis
    description: Activated endothelium promotes coagulation and vascular occlusion.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - tissue-factor and adhesion-molecule expression
    - thrombin generation
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports endothelial activation as a direct contributor to overt thrombosis.
  - target: Livedo Reticularis
    description: Cutaneous vascular involvement in APS can manifest as livedo reticularis.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:26223086
      reference_title: "Livedo Reticularis: An Enigma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Livedo reticularis is a common cutaneous manifestation of APS and may be a prognostic marker of more severe disease.
      explanation: This directly supports livedo reticularis as a cutaneous APS manifestation.
  - target: Livedo racemosa
    description: Cutaneous vascular involvement in APS can manifest as livedo racemosa.
    causal_link_type: UNKNOWN
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0033260 | Livedo racemosa | Frequent (79-30%)"
      explanation: Orphanet records livedo racemosa as a frequent APS phenotype.
  - target: Cardiac valve thickening or vegetation
    description: APS endothelial and thromboinflammatory injury can involve cardiac valves.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:23456852
      reference_title: "Valvular heart disease in antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %.
      explanation: This directly supports cardiac valve disease as a frequent cardiac manifestation of APS.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
    explanation: This review supports endothelial activation as a central APS mechanism.
- name: Monocyte tissue factor induction
  description: Activated monocytes upregulate tissue factor and intensify thrombin generation.
  cell_types:
  - preferred_term: monocyte
    term:
      id: CL:0000576
      label: monocyte
  downstream:
  - target: Arterial and venous thrombosis
    description: Monocyte-derived tissue factor accelerates coagulation and promotes thrombus formation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - tissue-factor-dependent coagulation
    - thrombin generation
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This directly supports the edge from monocyte tissue factor induction to thrombosis.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
    explanation: This review supports monocyte activation with tissue factor overproduction as a core APS mechanism.
- name: Platelet activation
  description: Platelets exposed to aPL signaling become activated and generate thromboxane-dependent prothrombotic amplification.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: platelet activation
    term:
      id: GO:0030168
      label: platelet activation
  downstream:
  - target: Arterial and venous thrombosis
    description: Activated platelets reinforce thrombus growth and stabilize vascular occlusion.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports platelet activation and thromboxane signaling as a direct contributor to APS thrombosis.
  - target: Thrombocytopenia
    description: Platelet involvement in APS is associated with thrombocytopenia.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:29316193
      reference_title: "Thrombocytopenia in high-risk patients with antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS).
      explanation: This directly supports thrombocytopenia as a common hematologic APS feature.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
    explanation: This review supports platelet activation as a discrete prothrombotic mechanism in APS.
  - reference: PMID:33878780
    reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
    explanation: This confirms platelet activation as part of a broader APS prothrombotic program.
- name: Complement activation
  description: >-
    Complement activation is a thromboinflammatory and placental-injury
    amplifier supported most strongly by experimental models and selected human
    biomarker or tissue studies; its contribution varies across APS phenotypes.
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Coagulation and fibrinolytic imbalance
    description: Complement activation and abnormal hemostasis can reinforce one another, but their ordering is context dependent.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:33878780
      reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
      explanation: This supports a linked disturbance but not a fixed causal direction.
  - target: Placental immune injury
    description: Complement deposition at the maternal-fetal interface promotes placental inflammation and perfusion failure.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:19557318
      reference_title: "Predictors of pregnancy outcome in antiphospholipid syndrome: a review."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: Moreover low levels of complement components are related to an increased incidence of obstetrical complications, suggesting that placental deposition of immune complexes and activation of complement cascade may contribute to placental failure APS related.
      explanation: This supports the mechanistic branch from complement activation to placental injury.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Complement activation might have a central pathogenetic role.
    explanation: This review identifies complement as a core amplifier of APS pathogenesis.
- name: Coagulation and fibrinolytic imbalance
  description: >-
    Increased tissue-factor/thrombin-generating activity and impaired fibrin
    clearance shift hemostasis toward formation and persistence of thrombi.
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
  - preferred_term: fibrinolysis
    term:
      id: GO:0042730
      label: fibrinolysis
  downstream:
  - target: Arterial and venous thrombosis
    description: Failure to lyse fibrin-rich clots contributes to recurrent thrombosis in arteries, veins, and microvessels.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33878780
      reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations.
      explanation: This supports association with thrombotic APS; the direct edge is a mechanistic interpretation of impaired clot clearance.
  evidence:
  - reference: PMID:33878780
    reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations.
    explanation: This supports impaired fibrinolysis as one component of the APS prothrombotic state.
- name: Trigger-dependent thromboinflammatory amplification
  description: >-
    Persistent aPL create susceptibility, but overt thrombosis is often
    intermittent. Infection, inflammation, vascular injury, surgery, pregnancy,
    or interruption of anticoagulation can supply an additional trigger; this
    two-hit model is useful but is not universal, especially for obstetric APS.
  downstream:
  - target: Arterial and venous thrombosis
    description: >-
      A second inflammatory or vascular insult can amplify endothelial,
      cellular, complement, and coagulation pathways enough to precipitate an
      occlusive event.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - vascular or inflammatory priming
    - tissue-factor and cellular activation
    - thrombin generation
    evidence:
    - reference: PMID:29867951
      reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: According to the two-hit hypothesis, the anti-PL antibody induces a thrombophilic state, but requires a second condition (e.g., an infection) for clotting to take place.
      explanation: The review supports this model while also describing its limitations.
  - target: Catastrophic microvascular thrombosis
    description: >-
      Infection, surgery, trauma, anticoagulation interruption, and malignancy
      often precede CAPS, but temporal association does not establish that one
      trigger is necessary or sufficient.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:39644034
      reference_title: "Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: CAPS is often preceded by triggering factors such as infection, surgery, trauma, anticoagulation discontinuation, and malignancy.
      explanation: This supports a trigger-associated CAPS branch while retaining causal uncertainty.
  evidence:
  - reference: PMID:29867951
    reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: infusion of anti-PL antibodies alone into the experimental animal models does not result in spontaneous thrombotic complications, thus suggesting the requirement for priming with a small vascular injury or injection of a low dose of LPS.
    explanation: This gives experimental support for an additional-trigger requirement in thrombosis models.
- name: Arterial and venous thrombosis
  description: >-
    Objectively documented venous or arterial thrombosis is a core clinical APS
    manifestation; competing thrombotic risks affect attribution and
    classification weight. Small-vessel disease is represented separately by
    suspected or established microvascular manifestations and by catastrophic
    APS.
  downstream:
  - target: Organ ischemia and damage accrual
    description: Vascular occlusion reduces tissue perfusion and causes cumulative neurologic, renal, pulmonary, and other organ injury.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22247356
      reference_title: "Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died
      explanation: This supports the direct progression from recurrent thrombosis to cumulative organ damage in APS.
  - target: Deep Vein Thrombosis
    description: APS venous thrombosis commonly includes deep vein thrombosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36575066
      reference_title: "[Venous thromboembolism in antiphosholipid syndrome]."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome.
      explanation: This supports deep-vein thrombotic events as part of frequent venous thromboembolism in APS.
  - target: Pulmonary Embolism
    description: APS venous thrombosis can manifest as pulmonary embolism.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17165009
      reference_title: "[Antiphospholipid syndrome]."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease).
      explanation: This explicitly lists pulmonary embolism among APS vaso-occlusive manifestations.
  - target: Ischemic stroke
    description: APS arterial thrombosis can cause ischemic stroke.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002140 | Ischemic stroke | Frequent (79-30%)"
      explanation: Orphanet records ischemic stroke as a frequent APS phenotype.
  - target: Transient ischemic attack
    description: APS arterial thrombosis can produce transient cerebral ischemia.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002326 | Transient ischemic attack | Frequent (79-30%)"
      explanation: Orphanet records transient ischemic attack as a frequent APS phenotype.
  - target: Arterial thrombosis
    description: APS procoagulant signaling manifests as arterial thrombosis.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0004420 | Arterial thrombosis | Frequent (79-30%)"
      explanation: Orphanet records arterial thrombosis as a frequent APS phenotype.
  - target: Venous thrombosis
    description: APS procoagulant signaling manifests as venous thrombosis.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0004936 | Venous thrombosis | Frequent (79-30%)"
      explanation: Orphanet records venous thrombosis as a frequent APS phenotype.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency.
    explanation: This review defines recurrent venous, arterial, and small-vessel thrombosis as a core APS event.
  - reference: PMID:24321419
    reference_title: "Risk factors for arterial thrombosis in antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid syndrome (APS) is associated with the risk of both arterial and venous thrombosis.
    explanation: This provides independent support that APS drives both arterial and venous thrombotic events.
- name: Placental immune injury
  description: >-
    At the maternal-fetal interface, aPL can perturb trophoblast function,
    complement regulation, inflammatory signaling, and placental perfusion.
    Placental thrombosis can occur but is not a universal explanation for
    pregnancy loss.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  locations:
  - preferred_term: placenta
    term:
      id: UBERON:0001987
      label: placenta
  downstream:
  - target: Pregnancy morbidity
    description: Placental dysfunction leads to miscarriage, preeclampsia, fetal growth restriction, and preterm delivery.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19665761
      reference_title: "Mechanisms of antiphospholipid antibody-associated pregnancy complications."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy complications, such as preeclampsia and preterm labor.
      explanation: This supports the direct edge from placental immune injury to recurrent miscarriage and late obstetric complications.
  evidence:
  - reference: PMID:19665761
    reference_title: "Mechanisms of antiphospholipid antibody-associated pregnancy complications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Recent clinical and experimental observations suggest that the pathophysiology of pregnancy failure in patients with APS may involve inflammation at the maternal-fetal interface and disruption of normal trophoblast function and survival, rather than a pro-thrombotic event.
    explanation: This supports placental inflammation and trophoblast dysfunction as a distinct APS mechanism.
  - reference: PMID:19557318
    reference_title: "Predictors of pregnancy outcome in antiphospholipid syndrome: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It provides a non-invasive method for the study of uteroplacental blood flow, being able to detect a condition of impaired placental perfusion, due to the presence of circulating antiphospholipid antibodies (aPL).
    explanation: This supports impaired perfusion as one component of obstetric APS, not a universal lesion.
- name: Pregnancy morbidity
  description: >-
    The obstetric APS spectrum includes recurrent early pregnancy loss, fetal
    death, and delivery before 34 weeks because of severe preeclampsia or
    placental insufficiency. Other pregnancy complications may be associated
    but are not automatically APS-defining.
  downstream:
  - target: Miscarriage
    description: Obstetric APS can present with recurrent otherwise unexplained early pregnancy loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26815583
      reference_title: "[Antiphospholipid syndrome and pregnancy]."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
      explanation: This supports early pregnancy loss as part of the obstetric spectrum.
  - target: Stillbirth
    description: Obstetric APS can present with otherwise unexplained fetal death.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26815583
      reference_title: "[Antiphospholipid syndrome and pregnancy]."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
      explanation: This supports fetal death and stillbirth within the obstetric APS spectrum.
  - target: Preterm Birth
    description: >-
      Classification focuses on delivery before 34 weeks when caused by severe
      preeclampsia or placental insufficiency, rather than any preterm birth.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26815583
      reference_title: "[Antiphospholipid syndrome and pregnancy]."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
      explanation: This directly lists premature birth among obstetric morbidity in APS.
  - target: Preeclampsia
    description: Obstetric APS and placental insufficiency can manifest as preeclampsia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32413497
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia).
      explanation: This directly lists severe pre-eclampsia as a major pregnancy morbidity presentation of APS.
  - target: Intrauterine growth retardation
    description: Placental insufficiency in obstetric APS can restrict fetal growth.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:80
      reference_title: Antiphospholipid syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001511 | Intrauterine growth retardation | Very frequent (99-80%)"
      explanation: Orphanet records fetal growth restriction as an obstetric APS phenotype; its frequency should not be generalized beyond that source.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency.
    explanation: This supports pregnancy loss and preterm delivery as key downstream obstetric outcomes of APS.
  - reference: PMID:19557318
    reference_title: "Predictors of pregnancy outcome in antiphospholipid syndrome: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency.
    explanation: This supports the broader set of placental-insufficiency phenotypes that define obstetric APS.
- name: Organ ischemia and damage accrual
  description: Recurrent thrombotic occlusion causes cumulative injury across the brain, kidneys, lungs, and other organs.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: kidneys
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: lungs
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:22247356
    reference_title: "Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died
    explanation: This cohort demonstrates cumulative damage accrual in APS over time.
  - reference: PMID:27198137
    reference_title: "Renal involvement in primary antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: APSN is a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries, recanalizing thrombi in arteries and arterioles, and focal atrophy
    explanation: This supports kidney injury as a representative organ-damage consequence of APS vaso-occlusion.
  - reference: PMID:38368768
    reference_title: "Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: APS patients had a higher frequency of damage accrual. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual.
    explanation: This confirms that recurrent vascular injury in APS produces long-term damage accrual.
- name: Catastrophic microvascular thrombosis
  description: >-
    Catastrophic APS is the acute multiorgan extreme of APS, with rapidly
    developing large- and small-vessel thrombosis and frequent thrombotic
    microangiopathy; it is not simply a higher count of prior macrovascular
    events.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: kidneys
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: lungs
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:26753212
    reference_title: "[Catastrophic antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Catastrophic antiphospholipid syndrome is the most dangerous form of the antiphospholipid syndrome, which is characterized by rapid onset of thrombosis in small vessels of many organs and intravascular coagulation, thrombocytopenia and hemolytic anemia.
    explanation: This defines CAPS as widespread small-vessel thrombosis with hematologic complications.
  - reference: PMID:26753212
    reference_title: "[Catastrophic antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The syndrome develops over a short period of time with acute multi-organ failure, including kidney, respiratory, cardiovascular, central nervous system and adrenal glands, often associated with disseminated thrombotic microangiopathy.
    explanation: This supports acute multiorgan failure from disseminated microvascular thrombosis as the most severe APS mechanistic outcome.
phenotypes:
- category: Thrombosis
  name: Deep Vein Thrombosis
  diagnostic: true
  notes: >-
    An objectively documented deep venous thrombosis can satisfy a clinical APS
    domain; provoking and competing risks affect attribution and classification
    weight, and the event does not establish APS without the aPL context.
  evidence:
  - reference: PMID:36575066
    reference_title: "[Venous thromboembolism in antiphosholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome.
    explanation: The reference mentions that venous thromboembolism, which includes deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome (APS).
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Includes (but is not limited to) pulmonary embolism, deep vein thrombosis of the legs/arms, splanchnic thrombosis, renal vein thrombosis, cerebral venous thrombosis, and retinal vein thrombosis/occlusion."
    explanation: The current classification definition explicitly includes deep-vein thrombosis within macrovascular VTE.
  phenotype_term:
    preferred_term: Deep venous thrombosis
    term:
      id: HP:0002625
      label: Deep venous thrombosis
- category: Pregnancy-Related
  name: Miscarriage
  context: Pregnancy
  diagnostic: true
  notes: >-
    The 2023 low-weight obstetric item requires three or more consecutive,
    otherwise unexplained prefetal losses before 10 weeks and/or early fetal
    deaths from 10 through 15 weeks 6 days. It does not by itself reach the
    three-point clinical classification threshold; a single sporadic early
    miscarriage is not sufficient to establish APS.
  evidence:
  - reference: PMID:26815583
    reference_title: "[Antiphospholipid syndrome and pregnancy]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: This directly identifies recurrent first-trimester loss as obstetric APS morbidity.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: occurrence of 3 or more consecutive prefetal deaths (at<10 weeks) and/or early fetal deaths (at 10–16 weeks)
    explanation: This supplies the current recurrence and gestational boundaries for the low-weight obstetric item.
  phenotype_term:
    preferred_term: Miscarriage
- category: Pregnancy-Related
  name: Stillbirth
  context: Pregnancy
  diagnostic: true
  notes: >-
    The 2023 obstetric domain includes otherwise unexplained fetal death from 10
    weeks through 34 weeks, with gestation and recurrence affecting weight. The
    The Stillbirth label captures only part of that broader fetal-death domain;
    alternative fetal, placental, and maternal causes must be assessed.
  evidence:
  - reference: PMID:26815583
    reference_title: "[Antiphospholipid syndrome and pregnancy]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: This directly identifies stillbirth and intrauterine death in obstetric APS.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: or one or more fetal deaths (at≥16 weeks to<34 weeks) alone
    explanation: This supplies the current later-fetal-death gestational boundary.
  phenotype_term:
    preferred_term: Stillbirth
- category: Pregnancy-Related
  name: Preterm Birth
  context: Pregnancy
  diagnostic: true
  notes: >-
    The defining obstetric context is delivery before 34 weeks because of severe
    preeclampsia or placental insufficiency; preterm birth from another cause is
    not automatically attributable to APS.
  evidence:
  - reference: PMID:26815583
    reference_title: "[Antiphospholipid syndrome and pregnancy]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: The reference lists premature birth (preterm birth) as a form of obstetric morbidity associated with APS, supporting its categorization as a pregnancy-related phenotype.
  - reference: PMID:34280554
    reference_title: "Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Patients with lupus anticoagulant positivity had an increased risk of preeclampsia (OR 2.10, p = 0.02, I2 = 48%), SGA (OR 1.78, p < 0.01, I2 = 0%) and preterm birth (OR 3.56, p = 0.01, I2 = 48%)
    explanation: The meta-analysis found that APS patients, especially those with lupus anticoagulant positivity, have an increased risk of preterm birth, supporting the statement that APS phenotypes include pregnancy-related complications such as preterm birth.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Preeclampsia with severe features OR placental insufficiency with severe features (<34 weeks) with or without fetal death
    explanation: This supplies the severe-feature and gestational boundary rather than treating every preterm birth as APS-defining.
  phenotype_term:
    preferred_term: Preterm Birth
    term:
      id: HP:0001622
      label: Premature birth
- category: Cardiovascular
  name: Cardiac valve thickening or vegetation
  notes: >-
    Valve thickening and sterile vegetation are nonthrombotic clinical-domain
    manifestations in the 2023 classification system; infective endocarditis
    and other valve disorders must be excluded. Reported prevalence varies with
    cohort and echocardiographic method, so no universal frequency is assigned.
  evidence:
  - reference: PMID:17916990
    reference_title: "The Heart and APS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic.
    explanation: A high prevalence reported with transesophageal echocardiography illustrates sensitivity to ascertainment method.
  - reference: PMID:23456852
    reference_title: "Valvular heart disease in antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %.
    explanation: The lower prevalence estimate in this review underscores cohort and method dependence.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic)
    explanation: This confirms cardiac-valve findings as a current classification domain.
  phenotype_term:
    preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
- category: Pregnancy-Related
  context: Pregnancy
  name: Preeclampsia
  diagnostic: true
  notes: >-
    The APS classification manifestation is severe preeclampsia leading to
    delivery before 34 weeks, not preeclampsia of any severity or gestation.
  evidence:
  - reference: PMID:26815583
    reference_title: "[Antiphospholipid syndrome and pregnancy]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: This supports preeclampsia within obstetric APS without assigning a universal frequency.
  - reference: PMID:32413497
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia).
    explanation: This specifically identifies severe preeclampsia as a major obstetric presentation.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Preeclampsia with severe features OR placental insufficiency with severe features (<34 weeks) with or without fetal death
    explanation: This directly supports the severe-feature and less-than-34-week boundary.
  phenotype_term:
    preferred_term: Preeclampsia
    term:
      id: MONDO:0005081
      label: preeclampsia
- category: Hematologic
  name: Thrombocytopenia
  notes: >-
    Usually mild-to-moderate. It was traditionally considered a non-criteria
    manifestation but is a weighted hematologic domain in the 2023 ACR/EULAR
    research-classification system; it is not specific for APS. Prevalence
    varies substantially with platelet threshold, cohort, and CAPS status, so
    no universal frequency is assigned.
  evidence:
  - reference: PMID:35536236
    reference_title: "Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our cohort included 74 (33.94%) patients with thrombocytopenia and 144 patients with a continuous normal platelet count.
    explanation: This quantifies thrombocytopenia in one prospective primary-APS cohort without generalizing the rate.
  - reference: PMID:18417261
    reference_title: "The hematologic manifestations of the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thrombocytopenia is frequently found in APS patients, its incidence has ranged from 22-42% in different series
    explanation: This review explicitly documents between-series variation.
  - reference: PMID:29316193
    reference_title: Thrombocytopenia in high-risk patients with antiphospholipid syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Prevalence of thrombocytopenia was 6% and 100% in patients who developed the catastrophic form.
    explanation: This selected triple-positive cohort demonstrates strong dependence on CAPS status and cohort definition.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thrombocytopenia (20–130×109 /liter)"
    explanation: This documents thrombocytopenia as a weighted 2023 clinical domain.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Dermatologic
  name: Livedo Reticularis
  notes: >-
    Livedo reticularis is reported in APS but is nonspecific. The 2023
    microvascular classification domain distinguishes persistent, irregular
    livedo racemosa from uniform, reversible livedo reticularis and does not
    score the latter.
  evidence:
  - reference: PMID:26223086
    reference_title: "Livedo Reticularis: An Enigma."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Livedo reticularis is a common cutaneous manifestation of APS and may be a prognostic marker of more severe disease.
    explanation: This reference states that livedo reticularis is a common cutaneous manifestation of APS, supporting its categorization as a dermatologic manifestation.
  phenotype_term:
    preferred_term: Livedo Reticularis
    term:
      id: HP:0033505
      label: Livedo reticularis
- category: Neurologic
  name: Migraine Headaches
  notes: >-
    Migraine is a reported non-criteria association and is common in the general
    population. It should not be attributed to APS without evaluating more
    likely causes and does not itself establish thrombotic APS.
  phenotype_term:
    preferred_term: Migraine Headaches
    term:
      id: HP:0002076
      label: Migraine
  evidence:
  - reference: PMID:27423434
    reference_title: "Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Migraine is the most commonly reported type of headache in APS/aPL-positive patients.
    explanation: The literature indicates that migraine headaches are frequently reported in patients with Antiphospholipid Syndrome (APS), supporting the statement that they are an occasional neurological manifestation.
- category: Cardiovascular
  name: Pulmonary Embolism
  diagnostic: true
  notes: >-
    Pulmonary embolism is a qualifying macrovascular venous thromboembolism
    when objectively confirmed. Competing risks affect attribution and
    classification weight, and APS still requires the persistent aPL context.
  evidence:
  - reference: PMID:17165009
    reference_title: "[Antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease).
    explanation: This review explicitly lists pulmonary embolism among the vaso-occlusive manifestations of APS.
  - reference: PMID:23073594
    reference_title: "[Analysis of risk factors in development of thrombosis in patients with antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Deep vein thrombosis of lower extremity (37.7%) and cerebral infarction (24.59%) were the most common thrombosis events, and then pulmonary embolism, thrombotic microangiopathy and renal artery thrombosis were also common in APS patients.
    explanation: This cohort study identifies pulmonary embolism as a common thrombotic manifestation in APS patients.
  phenotype_term:
    preferred_term: Pulmonary embolism
    term:
      id: HP:0002204
      label: Pulmonary embolism
- name: "Intrauterine growth retardation"
  category: Reproductive
  context: Pregnancy
  diagnostic: true
  description: >-
    Fetal growth restriction can reflect placental insufficiency in obstetric
    APS. The 2023 classification domain requires severe placental-insufficiency
    features and onset leading to delivery before 34 weeks; growth restriction
    alone is not specific for APS.
  phenotype_term:
    preferred_term: "Intrauterine growth retardation"
    term:
      id: HP:0001511
      label: "Intrauterine growth retardation"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001511 | Intrauterine growth retardation | Very frequent (99-80%)"
    explanation: Orphanet records fetal growth restriction as an APS-associated pregnancy phenotype, but its source-specific frequency is not generalized here.
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Intrauterine fetal growth restriction defined as biometry indicating estimated fetal weight of less than the 10th percentile
    explanation: This grounds fetal growth restriction within the current severe placental-insufficiency definition; additional severe features are still required.
- name: "Ischemic stroke"
  category: Neurologic
  diagnostic: true
  description: >-
    Objectively confirmed ischemic stroke can satisfy an arterial-thrombosis
    clinical domain, but APS requires the persistent aPL context and assessment
    of conventional vascular and embolic causes.
  phenotype_term:
    preferred_term: "Ischemic stroke"
    term:
      id: HP:0002140
      label: "Ischemic stroke"
  evidence:
  - reference: PMID:24741580
    reference_title: "Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Typically, neurological manifestations of APS include thrombosis of cerebral vessels leading to stroke
    explanation: This supports cerebral arterial thrombosis as the mechanism of ischemic stroke in APS.
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002140 | Ischemic stroke | Frequent (79-30%)"
    explanation: Orphanet records ischemic stroke as an APS phenotype; the source-specific frequency is not generalized.
- name: "Transient ischemic attack"
  category: Neurologic
  description: >-
    TIA is reported in APS but lacks tissue-confirmed infarction and should not
    automatically be counted as a qualifying arterial thrombosis; alternative
    cerebrovascular causes require evaluation.
  phenotype_term:
    preferred_term: "Transient ischemic attack"
    term:
      id: HP:0002326
      label: "Transient ischemic attack"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002326 | Transient ischemic attack | Frequent (79-30%)"
    explanation: Orphanet records TIA as an associated APS phenotype without resolving its diagnostic specificity.
- name: "Antiphospholipid antibody positivity"
  category: Immunologic
  diagnostic: true
  description: >-
    Persistent criterion aPL positivity is required for APS classification, but
    it is not sufficient without an associated clinical manifestation.
  phenotype_term:
    preferred_term: "Antiphospholipid antibody positivity"
    term:
      id: HP:0003613
      label: "Antiphospholipid antibody positivity"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003613 | Antiphospholipid antibody positivity | Frequent (79-30%)"
    explanation: Orphanet records aPL positivity as an APS laboratory phenotype; no universal frequency is inferred.
- name: "Arterial thrombosis"
  category: Cardiovascular
  diagnostic: true
  description: >-
    Objectively confirmed arterial thrombosis is a core clinical APS
    manifestation, but conventional arterial risk factors and competing embolic
    causes affect attribution and classification weight.
  phenotype_term:
    preferred_term: "Arterial thrombosis"
    term:
      id: HP:0004420
      label: "Arterial thrombosis"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004420 | Arterial thrombosis | Frequent (79-30%)"
    explanation: Orphanet records arterial thrombosis as an APS phenotype without establishing a universal rate.
- name: "Venous thrombosis"
  category: Cardiovascular
  diagnostic: true
  description: >-
    Objectively confirmed venous thromboembolism is a core clinical APS
    manifestation; provoking factors must be incorporated into attribution,
    classification weight, and recurrence-risk assessment.
  phenotype_term:
    preferred_term: "Venous thrombosis"
    term:
      id: HP:0004936
      label: "Venous thrombosis"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004936 | Venous thrombosis | Frequent (79-30%)"
    explanation: Orphanet records venous thrombosis as an APS phenotype without establishing a universal rate.
- name: "Anticardiolipin IgG antibody positivity"
  category: Immunologic
  diagnostic: true
  description: Persistent moderate- or high-level IgG anticardiolipin positivity is a criterion laboratory finding; low or transient positivity is less specific.
  phenotype_term:
    preferred_term: "Anticardiolipin IgG antibody positivity"
    term:
      id: HP:0020136
      label: "Anticardiolipin IgG antibody positivity"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0020136 | Anticardiolipin IgG antibody positivity | Frequent (79-30%)"
    explanation: Orphanet records anticardiolipin IgG positivity as an APS laboratory phenotype.
- name: "Anticardiolipin IgM antibody positivity"
  category: Immunologic
  diagnostic: true
  description: Persistent moderate- or high-level IgM anticardiolipin positivity is a criterion laboratory finding, but isolated IgM receives lower weight in the 2023 classification system.
  phenotype_term:
    preferred_term: "Anticardiolipin IgM antibody positivity"
    term:
      id: HP:0020137
      label: "Anticardiolipin IgM antibody positivity"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0020137 | Anticardiolipin IgM antibody positivity | Frequent (79-30%)"
    explanation: Orphanet records anticardiolipin IgM positivity as an APS laboratory phenotype.
- name: "Lupus anticoagulant"
  category: Hematologic
  diagnostic: true
  description: >-
    Persistent lupus-anticoagulant activity is a criterion laboratory finding
    defined by functional coagulation assays. It is not a single antibody and
    can be difficult to interpret during anticoagulant therapy.
  phenotype_term:
    preferred_term: "Lupus anticoagulant"
    term:
      id: HP:0025343
      label: "Lupus anticoagulant"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0025343 | Lupus anticoagulant | Frequent (79-30%)"
    explanation: Orphanet records lupus anticoagulant as an APS laboratory phenotype.
- name: "Anti-beta 2 glycoprotein I antibody positivity"
  category: Immunologic
  diagnostic: true
  description: Persistent moderate- or high-level IgG or IgM anti-beta2GPI positivity is a criterion laboratory finding; isotype and titer affect classification weight and risk.
  phenotype_term:
    preferred_term: "Anti-beta 2 glycoprotein I antibody positivity"
    term:
      id: HP:0032376
      label: "Anti-beta 2 glycoprotein I antibody positivity"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0032376 | Anti-beta 2 glycoprotein I antibody positivity | Frequent (79-30%)"
    explanation: Orphanet records anti-beta2GPI positivity as an APS laboratory phenotype.
- name: "Livedo racemosa"
  category: Dermatologic
  description: >-
    Persistent, irregular, broken, asymmetric livedo racemosa can support the
    suspected microvascular clinical domain after alternative causes are
    excluded; it is distinct from reversible symmetric livedo reticularis.
  phenotype_term:
    preferred_term: "Livedo racemosa"
    term:
      id: HP:0033260
      label: "Livedo racemosa"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0033260 | Livedo racemosa | Frequent (79-30%)"
    explanation: Orphanet records livedo racemosa as an APS-associated cutaneous phenotype.
- name: "Anti-beta-2-Glycoprotein I IgG antibody positivity"
  category: Immunologic
  diagnostic: true
  description: Persistent IgG anti-beta2GPI positivity is a criterion laboratory finding, with moderate and high levels weighted separately in the 2023 system.
  phenotype_term:
    preferred_term: "Anti-beta-2-Glycoprotein I IgG antibody positivity"
    term:
      id: HP:0034156
      label: "Anti-beta-2-Glycoprotein I IgG antibody positivity"
  evidence:
  - reference: ORPHA:80
    reference_title: Antiphospholipid syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0034156 | Anti-beta-2-Glycoprotein I IgG antibody positivity | Frequent (79-30%)"
    explanation: Orphanet records IgG anti-beta2GPI positivity as an APS laboratory phenotype.
biochemical:
- name: Persistent criterion antiphospholipid-antibody profile
  presence: Positive
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients with persistent antiphospholipid antibodies (aPL)
    explanation: Persistent aPL are part of the disease definition, but require an associated clinical manifestation.
- name: Lupus Anticoagulant
  presence: Positive
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: lupus anticoagulant functional coagulation assays
    explanation: Lupus anticoagulant is represented correctly as a functional assay domain and requires persistence for full classification weight.
- name: Anti-Cardiolipin Antibodies
  presence: Positive
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β2-glycoprotein I antibodies
    explanation: This defines anticardiolipin IgG/IgM as one of the two solid-phase criterion assay families.
- name: Beta-2 Glycoprotein I Antibodies
  presence: Positive
  evidence:
  - reference: PMID:37640450
    reference_title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β2-glycoprotein I antibodies
    explanation: This defines anti-beta2GPI IgG/IgM as a criterion solid-phase assay family.
genetic:
- name: HLA class II regulatory locus near HLA-DRA
  subtype: Primary antiphospholipid syndrome
  association: Genome-wide-significant common-variant susceptibility locus
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    This is a locus-level association in a European-ancestry GWAS with 482
    affected individuals. It does not establish HLA-DRA itself as the causal
    gene or imply Mendelian causation.
  evidence:
  - reference: PMID:38973605
    reference_title: "A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We revealed genetic associations with PAPS in a regulatory locus within
      the HLA class II region near HLA-DRA and in STAT1-STAT4 with a genome-wide
      level of significance; 34 additional suggestive genetic susceptibility
      loci for PAPS were also identified.
    explanation: >-
      The primary GWAS directly supports a genome-wide-significant HLA class II
      region susceptibility signal while leaving the causal gene unresolved.
- name: STAT1-STAT4 susceptibility locus
  subtype: Primary antiphospholipid syndrome
  association: Genome-wide-significant common-variant susceptibility locus
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    This is a locus-level association in a European-ancestry GWAS with 482
    affected individuals. The signal does not resolve STAT1, STAT4, or another
    linked element as causal and does not imply Mendelian causation.
  evidence:
  - reference: PMID:38973605
    reference_title: "A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We revealed genetic associations with PAPS in a regulatory locus within
      the HLA class II region near HLA-DRA and in STAT1-STAT4 with a genome-wide
      level of significance; 34 additional suggestive genetic susceptibility
      loci for PAPS were also identified.
    explanation: >-
      The primary GWAS directly supports a genome-wide-significant STAT1-STAT4
      region susceptibility signal while leaving the causal element unresolved.
treatments:
- name: Long-term warfarin anticoagulation
  action_category: THERAPEUTIC
  description: >-
    Vitamin K antagonist therapy is standard secondary prevention for
    thrombotic APS. For a first unprovoked venous event, the usual target INR is
    2-3; after an arterial event, INR 2-3 versus 3-4 is individualized to
    thrombosis and bleeding risk. Recurrent thrombosis despite adequate therapy
    prompts adherence/INR review and selected escalation rather than assuming
    universal treatment failure.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: warfarin
      term:
        id: CHEBI:10033
        label: warfarin
  target_phenotypes:
  - preferred_term: Venous thrombosis
    term:
      id: HP:0004936
      label: Venous thrombosis
  - preferred_term: Arterial thrombosis
    term:
      id: HP:0004420
      label: Arterial thrombosis
  target_mechanisms:
  - target: Coagulation and fibrinolytic imbalance
    treatment_effect: INHIBITS
    description: Vitamin K antagonism reduces thrombin generation and recurrence risk; it does not remove aPL or normalize upstream autoimmunity.
    evidence:
    - reference: PMID:31092409
      reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
      supports: PARTIAL
      evidence_source: OTHER
      snippet: Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3.
      explanation: The recommendation supports targeting the coagulation arm, while the molecular treatment effect is a pharmacologic inference.
  evidence:
  - reference: PMID:31092409
    reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3.
    explanation: This directly supports long-term VKA therapy and the usual venous target INR.
  - reference: PMID:31092409
    reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In patients with APS with first arterial thrombosis, treatment with VKA with INR 2-3 or INR 3-4 is recommended, considering the individual's bleeding/thrombosis risk.
    explanation: This supports individualized VKA intensity after arterial thrombosis.
  - reference: PMID:36328154
    reference_title: "Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with thrombotic antiphospholipid syndrome randomized to DOACs compared with VKAs appear to have increased risk for arterial thrombosis.
    explanation: Randomized-trial meta-analysis argues against routine DOAC substitution, especially when arterial risk is relevant.
  notes: >-
    Rivaroxaban should not be used in triple-aPL-positive APS. Evidence for DOACs
    in lower-risk single- or double-positive venous-only populations is less
    definitive, so anticoagulant choice is individualized rather than implying
    that every DOAC exposure has identical risk.
- name: Heparin plus low-dose aspirin in pregnancy
  action_category: THERAPEUTIC
  description: >-
    Low-dose aspirin plus prophylactic-dose heparin is recommended during
    pregnancy for women with prior obstetric APS. Dosing and peripartum timing
    require individualized obstetric and thrombosis planning; this statement
    does not extend the regimen to every aPL-positive pregnancy.
  treatment_term:
    preferred_term: aspirin therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: heparin
      term:
        id: CHEBI:28304
        label: heparin
    - preferred_term: aspirin
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  target_phenotypes:
  - preferred_term: Miscarriage
  - preferred_term: Stillbirth
  - preferred_term: Preterm Birth
    term:
      id: HP:0001622
      label: Premature birth
  target_mechanisms:
  - target: Platelet activation
    treatment_effect: INHIBITS
    description: Low-dose aspirin inhibits platelet thromboxane signaling within the obstetric regimen.
    evidence:
    - reference: PMID:31092409
      reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
      supports: PARTIAL
      evidence_source: OTHER
      snippet: In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended.
      explanation: The clinical recommendation supports the regimen; platelet-pathway attribution follows aspirin pharmacology.
  - target: Coagulation and fibrinolytic imbalance
    treatment_effect: INHIBITS
    description: Heparin suppresses coagulation within the combined regimen and may have additional placental effects.
    evidence:
    - reference: PMID:31092409
      reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
      supports: PARTIAL
      evidence_source: OTHER
      snippet: In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended.
      explanation: The clinical recommendation supports heparin use; this does not prove that anticoagulation is the sole placental mechanism.
  evidence:
  - reference: PMID:31092409
    reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended.
    explanation: This directly supports the standard obstetric regimen and its population boundary.
- name: Adjunct hydroxychloroquine
  action_category: THERAPEUTIC
  description: >-
    Hydroxychloroquine may be considered as an add-on when pregnancy
    complications recur despite aspirin plus heparin. It is not a substitute
    for anticoagulation in thrombotic APS, and evidence for APS-specific benefit
    remains limited.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxychloroquine
      term:
        id: CHEBI:5801
        label: hydroxychloroquine
  target_phenotypes:
  - preferred_term: Miscarriage
  target_mechanisms:
  - target: Placental immune injury
    treatment_effect: INHIBITS
    description: Hydroxychloroquine is used as an immunomodulatory adjunct, but the clinical recommendation does not establish one placental molecular target.
    evidence:
    - reference: PMID:31092409
      reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
      supports: PARTIAL
      evidence_source: OTHER
      snippet: In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered.
      explanation: This supports use as an obstetric add-on while leaving the specific placental mechanism uncertain.
  evidence:
  - reference: PMID:31092409
    reference_title: EULAR recommendations for the management of antiphospholipid syndrome in adults.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered.
    explanation: The guideline frames hydroxychloroquine as an option for recurrence, not routine first-line monotherapy.
- name: Catastrophic APS combination therapy
  action_category: THERAPEUTIC
  description: >-
    Suspected catastrophic APS is a medical emergency. Standard combination
    treatment uses therapeutic intravenous heparin plus glucocorticoids and
    plasma exchange and/or IVIG while the precipitating factor and organ failure
    are treated. Diagnostic testing should not delay therapy when suspicion is
    high.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: heparin
      term:
        id: CHEBI:28304
        label: heparin
    - preferred_term: glucocorticoid
      term:
        id: CHEBI:24261
        label: glucocorticoid
  target_mechanisms:
  - target: Coagulation and fibrinolytic imbalance
    treatment_effect: INHIBITS
    description: Intravenous heparin suppresses the coagulation arm of catastrophic thromboinflammation.
    evidence:
    - reference: PMID:39644034
      reference_title: "Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: Management of CAPS requires "triple therapy" with glucocorticoids, intravenous heparin, therapeutic plasma exchange, and/or intravenous immunoglobulin.
      explanation: This supports heparin as a required component; the target-mechanism statement reflects anticoagulant pharmacology.
  - target: Complement activation
    treatment_effect: INHIBITS
    description: Plasma exchange, IVIG, and glucocorticoids broadly modulate antibody-driven inflammation; their benefit is not proof that one complement step dominates every CAPS case.
    evidence:
    - reference: PMID:27886797
      reference_title: "Catastrophic antiphospholipid syndrome: The current management approach."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: from the experimental or basic point of view, there is only indirect evidence to advocate the use of these immunomodulatory therapies (GC, PE, and IVIG) in CAPS.
      explanation: This explicitly limits mechanistic confidence for the immunomodulatory components.
  evidence:
  - reference: PMID:39644034
    reference_title: "Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Management of CAPS requires "triple therapy" with glucocorticoids, intravenous heparin, therapeutic plasma exchange, and/or intravenous immunoglobulin.
    explanation: This directly supports current combination management.
- name: Rituximab or eculizumab for refractory catastrophic APS
  action_category: THERAPEUTIC
  description: >-
    B-cell depletion with rituximab or C5 inhibition with eculizumab may be used
    in selected refractory CAPS, but support is based on poor-quality evidence
    rather than randomized trials. These agents are escalation options, not
    routine substitutes for combination therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
    - preferred_term: eculizumab
      term:
        id: NCIT:C48386
        label: Eculizumab
  target_mechanisms:
  - target: Autoantibody generation against beta2GPI and phospholipid complexes
    treatment_effect: INHIBITS
    description: Rituximab depletes CD20-positive B cells upstream of ongoing autoantibody production.
    evidence:
    - reference: PMID:27886797
      reference_title: "Catastrophic antiphospholipid syndrome: The current management approach."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: The first blocks CD20, a surface protein expressed on the cytoplasmic membrane of B cells, and decreases the generation of pathogenic autoantibodies such as antiphospholipid (aPL) antibodies.
      explanation: This supports the proposed B-cell/aPL target, but clinical outcome evidence remains limited.
  - target: Complement activation
    treatment_effect: INHIBITS
    description: Eculizumab blocks C5 cleavage and terminal-complement-complex generation.
    evidence:
    - reference: PMID:27886797
      reference_title: "Catastrophic antiphospholipid syndrome: The current management approach."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: The second binds with high affinity to C5 complement protein, inhibiting its cleavage and thus preventing the generation of C5b-C9 complex.
      explanation: This directly supports the molecular target, while clinical efficacy evidence is limited to reports.
  evidence:
  - reference: PMID:39644034
    reference_title: "Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: Treatment for refractory disease is based on poor-quality evidence but includes anti-CD20 (rituximab) or anticomplement (eculizumab) monoclonal antibodies and other immunosuppressant agents, either alone or in combination.
    explanation: This supports selected refractory use and explicitly records the evidence limitation.
differential_diagnoses:
- name: Thrombotic thrombocytopenic purpura
  description: >-
    Thrombotic thrombocytopenic purpura can closely mimic catastrophic APS
    through thrombocytopenia, microangiopathic hemolysis, neurologic injury,
    renal dysfunction, and multiorgan ischemia.
  distinguishing_features:
  - Undetectable ADAMTS13 activity strongly favors thrombotic thrombocytopenic purpura.
  - >-
    Rapid multisite thrombosis and organ dysfunction in a patient with a
    qualifying APS clinical and persistent laboratory context support CAPS;
    aPL positivity alone and empiric anticoagulation do not distinguish CAPS
    from TTP.
  disease_term:
    preferred_term: thrombotic thrombocytopenic purpura
    term:
      id: MONDO:0018896
      label: thrombotic thrombocytopenic purpura
  evidence:
  - reference: PMID:10483019
    reference_title: "Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The differential diagnosis of CAPS includes thrombotic thrombocytopenic purpura (TTP) and this distinction may be difficult, but essential, for appropriate therapy.
    explanation: This directly identifies TTP as a core differential diagnosis for catastrophic APS.
  - reference: PMID:25879992
    reference_title: "Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The definitive marker for thrombotic thrombocytopenic purpura is undetectable ADAMTS 13 activity.
    explanation: This supports ADAMTS13 deficiency as a key laboratory feature distinguishing TTP from APS-related thrombotic microangiopathy.
- name: HELLP syndrome
  description: >-
    HELLP syndrome overlaps with obstetric APS and catastrophic APS through
    thrombocytopenia, hemolysis, liver injury, and severe pregnancy-associated
    maternal morbidity.
  distinguishing_features:
  - A pregnancy-specific pre-eclampsia context with hemolysis, elevated liver enzymes, and low platelet count favors HELLP syndrome.
  - Neurologic involvement, dialysis requirement, or absent disseminated intravascular coagulation raise concern for thrombotic microangiopathy or APS mimics rather than isolated HELLP.
  disease_term:
    preferred_term: HELLP syndrome
    term:
      id: MONDO:0008585
      label: HELLP syndrome
  evidence:
  - reference: PMID:25879992
    reference_title: "Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Pre-eclampsia complicated by severe HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome is a multi-organ disease, and can be difficult to differentiate from thrombotic microangiopathy (appearing as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome), acute fatty liver, systemic erythematous lupus, antiphospholipid syndrome and severe sepsis.
    explanation: This review explicitly names antiphospholipid syndrome among the major disorders that can be confused with severe HELLP syndrome.
  - reference: PMID:25879992
    reference_title: "Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Relevant identifiers to establish the most accurate diagnosis include the frequency of each disease and anamnestic data. Frank hemolysis, need for dialysis, neurological involvement and absence of disseminated intravascular coagulation are indicative of thrombotic microangiopathy.
    explanation: This supports specific distinguishing features that help separate HELLP syndrome from APS-related thrombotic microangiopathy.
- name: Systemic lupus erythematosus
  description: >-
    Systemic lupus erythematosus frequently co-occurs with APS and may be
    mistaken for primary APS when antiphospholipid antibodies are present
    alongside broader systemic autoimmune findings.
  distinguishing_features:
  - SLE-specific nephropathy, arthritis, cutaneous or neurologic lupus manifestations, anti-dsDNA, anti-Sm, or high-titer ANA favor systemic lupus erythematosus.
  - Strictly defined primary APS can satisfy some lupus classification items without progressing to clinical SLE on long-term follow-up.
  disease_term:
    preferred_term: systemic lupus erythematosus
    term:
      id: MONDO:0007915
      label: systemic lupus erythematosus
  evidence:
  - reference: PMID:30005859
    reference_title: "Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We successively excluded patients with (1) at least one "SLE-specific" manifestation (biopsy-proven SLE nephropathy, arthritis, cutaneous, or neurologic SLE manifestations, pericarditis, autoimmune haemolytic anaemia, oral and nasal ulcers, non-scarring alopecia, anti-dsDNA, and anti-Sm antibodies), (2) any other autoimmune connective tissue disease, and/or (3) antinuclear antibodies >1/320.
    explanation: This cohort analysis outlines the clinical and serologic features used to distinguish SLE from primary APS.
  - reference: PMID:30005859
    reference_title: "Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Because 28% of our patients with longstanding and strictly defined PAPS could be mistakenly classified as SLE, they were at risk of deleterious therapeutic management.
    explanation: This directly supports SLE as an important diagnostic pitfall and differential diagnosis for primary APS.
datasets:
- accession: DOI:10.1002/art.42947
  title: A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
  description: >-
    Large genome-wide association study resource for primary APS, used to
    identify susceptibility loci and compare the genetic architecture of APS
    with other immune-mediated diseases.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: GWAS
  sample_count: 5485
  conditions:
  - primary antiphospholipid syndrome
  - immune-mediated disease genetic comparison
  publication: PMID:38973605
  evidence:
  - reference: PMID:38973605
    reference_title: "A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METHODS: We performed a genome-wide association study comprising 5,485 individuals (482 affected individuals) of European ancestry."
    explanation: This supports the cohort size and GWAS design of a major primary APS genetics dataset.
- accession: DOI:10.1136/annrheumdis-2013-204600
  title: Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus
  description: >-
    Human monocyte microarray dataset comparing APS, APS plus SLE, SLE, and
    healthy donors to define inflammatory, atherosclerotic, and prothrombotic
    transcriptional programs.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: peripheral blood monocytes
    term:
      id: UBERON:0000178
      label: blood
    cell_type_term:
      preferred_term: monocyte
      term:
        id: CL:0000576
        label: monocyte
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
  sample_count: 190
  conditions:
  - primary antiphospholipid syndrome
  - antiphospholipid syndrome associated with systemic lupus erythematosus
  - systemic lupus erythematosus
  - healthy controls
  publication: PMID:24618261
  evidence:
  - reference: PMID:24618261
    reference_title: "Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METHODS: 129 patients (42 APS, 31 APS plus SLE and 56 SLE) and 61 healthy donors were included. Microarray expression profiling was performed in monocytes."
    explanation: This supports a disease-relevant monocyte transcriptomic dataset spanning APS and overlapping autoimmune comparator groups.
- accession: DOI:10.3389/fimmu.2021.702425
  title: Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome
  description: >-
    Urine proteomics dataset distinguishing primary thrombotic APS from primary
    obstetric APS using iTRAQ and liquid chromatography-tandem mass spectrometry.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: PROTEOMICS
  sample_types:
  - preferred_term: urine sample
    term:
      id: UBERON:0001088
      label: urine
    tissue_term:
      preferred_term: urine
      term:
        id: UBERON:0001088
        label: urine
  sample_count: 39
  conditions:
  - primary thrombotic antiphospholipid syndrome
  - primary obstetric antiphospholipid syndrome
  - healthy controls
  publication: PMID:34489952
  evidence:
  - reference: PMID:34489952
    reference_title: "Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Urine samples from 15 patients with TAPS, 9 patients with OAPS, and 15 healthy controls (HCs) were collected and analyzed using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis to identify differentially expressed proteins.
    explanation: This supports a human APS proteomics dataset spanning thrombotic and obstetric primary APS subgroups.
review_notes: >-
  Full evidence and mechanism review completed 2026-07-21. The disease boundary
  now separates APS from isolated aPL positivity, and diagnostic practice from
  research classification. Thrombotic, microvascular, valvular, hematologic,
  and narrowly defined obstetric manifestations are retained without assigning
  cohort-specific frequencies globally. Mechanistic edges distinguish
  antibody availability, cell activation, NET, complement, coagulation, and
  placental branches and explicitly preserve uncertain directionality.
  Treatment coverage is limited to guideline-supported anticoagulation and
  obstetric regimens, emergency combination treatment for CAPS, and clearly
  qualified refractory options.
disease_term:
  preferred_term: antiphospholipid syndrome
  term:
    id: MONDO:8000010
    label: antiphospholipid syndrome
classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Other clinical manifestations are cardiac valvular disease, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, and cognitive impairment.
      explanation: APS has prominent hematologic manifestations, including thrombocytopenia and hemolytic anaemia.
    - reference: PMID:10763209
      reference_title: "[Aspirin and antiphospholipid syndrome]."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Antiphospholipid syndrome is the most frequent cause of acquired thrombophilia.
      explanation: Acquired thrombophilia places APS within coagulation disorders.
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:16394638
      reference_title: "[Catastrophic antiphospholipid syndrome: CAPS]."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Antiphospholipid syndrome (APS) is well known as an autoimmune thrombotic syndrome with recurrent thromboses.
      explanation: This review explicitly describes APS as an autoimmune syndrome.
discussions:
- discussion_id: gap_aps_apl_production_cd4_dysregulation
  prompt: >-
    The antiphospholipid antibodies that define APS are pathogenic, yet the
    immune mechanisms that initiate and sustain their production remain poorly
    understood. Which upstream antigenic, environmental, or genetic trigger
    activates autoreactive aPL-specific CD4+ T cells, and is the observed CD4+
    T cell dysregulation (Th1/Th17 skewing, diminished Treg, a disturbed
    Tfh/Tfr axis) a primary driver of aPL production or a secondary consequence
    of established autoimmunity? Do the contradictory subset findings across
    cohorts reflect true APS phenotypic heterogeneity or unresolved
    methodological confounding?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#CD4+ T cell dysregulation and autoreactive B cell licensing
  - pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes
  - pathophysiology#Cell-surface beta2GPI binding
  rationale: >-
    aPL drive thrombosis and obstetric morbidity, but the autoimmune program
    that maintains chronic aPL production is unresolved, limiting
    mechanism-based therapy beyond anticoagulation. The Gaspar et al. (2026)
    review synthesizes candidate links between autoreactive aPL-specific CD4+ T
    cells and sustained aPL responses, alongside reports of Th1/Th17
    polarization, reduced Treg frequency or function, and a dysregulated
    follicular T-cell (Tfh/Tfr) axis in primary APS. A deliberately
    non-directional CD4+ T-cell dysregulation node represents this evidence in
    the pathophysiology graph.
    However, two gaps persist. First, the upstream trigger that activates
    aPL-specific CD4+ T cells is unknown, so the pathophysiology lacks a
    defined event upstream of the CD4+ dysregulation node. Second, the
    literature disagrees on which CD4+ T cell subsets dominate, and it is
    unclear whether CD4+ T cell dysregulation causes aPL production or follows
    it. Resolving the directionality and the trigger would determine whether
    T-B crosstalk is a viable therapeutic target and whether distinct immune
    profiles define APS subtypes.
  proposed_experiments:
  - experiment_id: exp_aps_cd4_longitudinal_apl_directionality
    name: Longitudinal CD4+ T cell immunophenotyping with aPL-specific T cell tracking in primary APS
    description: >-
      Enroll aPL-positive individuals spanning asymptomatic carriers, new-onset
      primary APS, and established primary APS, plus matched controls, and follow
      them longitudinally. At each visit, deep-immunophenotype circulating CD4+ T
      cell subsets (Th1, Th17, Treg, Tfh, Tfr, Tfh17-like) by spectral flow
      cytometry, quantify beta2GPI-reactive CD4+ T cells with antigen-specific
      assays, and measure aPL titres (anticardiolipin, anti-beta2GPI, lupus
      anticoagulant). Use standardized gating across sites to control the
      methodological variability the review highlights, and apply cross-lagged
      analysis to test whether T cell dysregulation precedes or follows changes
      in aPL titre.
    experiment_type:
      preferred_term: longitudinal immunophenotyping observational cohort study
    readouts:
    - name: aPL-specific CD4+ T cell frequency and polarization
      target: pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes
      description: >
        Measure the frequency and Th1/Th17/Tfh polarization of beta2GPI-reactive
        CD4+ T cells and test whether their expansion temporally precedes rising
        aPL titres, supporting a primary-driver role in autoantibody generation.
      assays:
      - preferred_term: antigen-specific T cell stimulation assay
      - preferred_term: spectral flow cytometry immunophenotyping
      direction: POSITIVE
    - name: Regulatory T and follicular regulatory cell deficit
      target: pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes
      description: >
        Quantify Treg and Tfr frequency and suppressive function to test whether
        a regulatory deficit accompanies the loss of tolerance that permits
        sustained aPL production.
      assays:
      - preferred_term: regulatory T cell suppression assay
      direction: NEGATIVE
    - name: aPL titre trajectory relative to T cell changes
      target: pathophysiology#Cell-surface beta2GPI binding
      description: >
        Track anticardiolipin, anti-beta2GPI, and lupus anticoagulant levels and
        relate their trajectory to preceding CD4+ T cell subset shifts to resolve
        directionality between T cell dysregulation and pathogenic antibody
        availability for cell-surface binding.
      assays:
      - preferred_term: antiphospholipid antibody titre assay
      direction: POSITIVE
    decision_criterion: >-
      A primary-driver model is supported if expansion of aPL-specific CD4+ T
      cells and a Tfh/Tfr imbalance reproducibly precede rises in aPL titre in
      converters across sites; a secondary-consequence model is supported if
      T cell dysregulation appears only after aPL elevation. Reproducible,
      site-concordant subset signatures that segregate patients into distinct
      immune profiles would favor true phenotypic heterogeneity over
      methodological artifact.
    would_support:
    - pathophysiology#Autoantibody generation against beta2GPI and phospholipid complexes
    - pathophysiology#Cell-surface beta2GPI binding
  evidence:
  - reference: PMID:42229606
    reference_title: "Dysregulation of helper, regulatory, and follicular CD4(+) T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: While the clinical role of aPL is well established, the immune mechanisms sustaining their production remain poorly understood.
    explanation: >-
      This review statement directly establishes that the mechanisms sustaining
      aPL production are unresolved, motivating the primary arm of this knowledge
      gap.
  - reference: PMID:42229606
    reference_title: "Dysregulation of helper, regulatory, and follicular CD4(+) T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Despite inconsistent findings across studies, likely reflecting phenotypical APS heterogeneity, distinct aPL profiles, and immunophenotyping methodological variations, the cumulative data support a model in which APS involves a coordinated disruption of CD4+ T cell homeostasis, encompassing both effector and regulatory arms.
    explanation: >-
      This passage documents the contradictory CD4+ T cell findings and the
      uncertainty over heterogeneity versus methodological confounding, motivating
      the secondary arm of this knowledge gap.

📚

References & Deep Research

Deep Research

Disorder ▸

Disorder

Name: Antiphospholipid Syndrome
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 99

Key Pathophysiology Nodes

Antibody Production
Blood Clot Formation
Impaired Blood Flow
Organ Damage
Pregnancy Complications
Chronic Complications
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1093/rheumatology/kead575
DOI:10.1093/rheumatology/keae397
DOI:10.1111/bjh.19635
DOI:10.3389/fimmu.2025.1639065
DOI:10.3389/fimmu.2025.1676578
DOI:10.3390/cells14050353
DOI:10.3390/ijms24043195
DOI:10.3390/jcm13144191
DOI:10.7759/cureus.66555

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 28 citations 2025-12-03T22:20:58.523511

Disease Pathophysiology Research Report

Target Disease - Disease Name: Antiphospholipid Syndrome (APS) - MONDO ID: not definitively assigned here - Category: Complex, autoimmune thrombo-inflammatory disease

Pathophysiology description - Core paradigm. APS is driven by antiphospholipid antibodies (aPL) that recognize phospholipid-binding proteins—most notably β2-glycoprotein I (β2GPI)—on vascular and placental cells, shifting hemostasis toward a prothrombotic and proinflammatory state. Anti-β2GPI (especially domain I-directed) and anti-cardiolipin antibodies, with lupus anticoagulant positivity, are necessary but insufficient; a “second hit” (e.g., infection, pregnancy, surgery) frequently precipitates clinically overt thrombosis or obstetric morbidity (two-hit model) (10.1111/bjh.19635, Jul 2024; 10.7759/cureus.66555, Aug 2024) (arachchillage2024guidelinesonthe pages 2-2, parepalli2024antiphospholipidsyndromeand pages 2-3). - aPL–β2GPI interactions and coagulation. Anti-β2GPI binds β2GPI on endothelial cells, monocytes, and platelets, inducing tissue factor (TF) expression and impairing anticoagulant/fibrinolytic balances (protein C/TFPI suppression; increased PAI-1), thereby enhancing thrombin generation and clot persistence (10.3390/jcm13144191, Jul 2024; 10.3389/fimmu.2025.1639065, Aug 2025; 10.3390/cells14050353, Feb 2025) (celia2024antiphospholipidsyndromeinsights pages 3-5, zhu2025noveladvanceson pages 3-4, bucci2025statinsasan pages 2-4). - Platelet and endothelial activation. aPL–β2GPI complexes activate platelets via ApoER2, GPIbα and αIIbβ3, triggering p38/PI3K–AKT signaling, ROS/TXA2 generation, and aggregation; endothelial cells upregulate NF-κB–dependent adhesion molecules (E-selectin/VCAM-1/ICAM-1), cytokines (IL-6/IL-8), and TF, reflecting a prothrombo-inflammatory transcriptomic program (10.3390/cells14050353; 10.1093/rheumatology/kead575, Feb 2024; 10.3390/jcm13144191) (bucci2025statinsasan pages 2-4, lopezpedrera2024newadvancesin pages 1-2, celia2024antiphospholipidsyndromeinsights pages 3-5). - Complement and NETs. Complement activation integrates with coagulation and cell activation. In APS kidney tissue, RNA-seq shows strong upregulation of C3/C4A/C4B and enrichment for type I IFN signaling; NET-related genes are also upregulated, implicating immunothrombosis at the organ level (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). Guidelines emphasize complement and NETs as important pathomechanisms, with CAPS representing an extreme thromboinflammatory state often precipitated by triggers (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Interferon/TLR axis. Multiple independent transcriptomic datasets show type I interferon-regulated genes (e.g., IFI6, IFI44, MX1, OAS1, RSAD2) are upregulated across APS, with links to thrombosis and preeclampsia; “a distinct signature comprising 11 IFN-induced genes” was reported in PBMCs (10.1093/rheumatology/kead575) (lopezpedrera2024newadvancesin pages 4-5). Anti-β2GPI signaling engages TLR4 (and TLR7/8) to activate p38/MEK/ERK and NF-κB, upregulating TF and adhesion molecules (10.3389/fimmu.2025.1639065) (zhu2025noveladvanceson pages 3-4). - Obstetric APS (OAPS) mechanisms. Beyond thrombosis, aPL directly perturb placental biology: trophoblast dysfunction, loss of annexin V shield, altered angiogenic signaling, and immune dysregulation contribute to placental insufficiency, fetal growth restriction, preeclampsia, and pregnancy loss; aPS/PT associates with obstetric complications (10.3390/ijms24043195, Feb 2023) (d’ippolito2023antiphospholipidsyndromein pages 4-5). Placental and endothelial inflammation signatures converge (IL-6/IL-8/selectins/ICAM/VCAM/TGF-β2) (10.1093/rheumatology/kead575) (lopezpedrera2024newadvancesin pages 1-2). - Systems immunothrombosis. Unbiased proteomics in aPL-positive individuals reveals a graded thromboinflammatory signature across clinical phenotypes—activation of coagulation, complement, neutrophil pathways, and ECM organization—increasing from aPL carriers to thrombotic and microvascular APS (10.3389/fimmu.2025.1676578, Oct 2025) (pine2025aproteomicmap pages 1-2).

Recent developments and latest research (priority 2023–2024) - Kidney transcriptomics (2024): Upregulated C3/C4A/C4B (logFC ~2.1–2.3) and IFN-α/β signaling; NETs-related genes increased in APS kidney biopsies, mirroring prior whole-blood signatures (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - IFN signatures (2024): “Upregulation of IFN-related genes in patients with APS” consistent across whole blood, PBMCs and neutrophils; an 11-gene IFN panel distinguished APS from controls (10.1093/rheumatology/kead575, Feb 2024) (lopezpedrera2024newadvancesin pages 4-5). - Endothelial gene programs (2024): aPL/β2GPI induce endothelial NF-κB/MAPK/TGF-β activation with IL-6/IL-8 and adhesion molecule upregulation; similar activation detected in APS placental tissue (10.1093/rheumatology/kead575) (lopezpedrera2024newadvancesin pages 1-2). - Guidelines synthesis (2024): APS hypercoagulability arises from cell activation (endothelium/monocyte/platelet/neutrophil), complement and NETs, with two-hit triggers; management emphasizes vitamin K antagonists (VKA) for thrombotic APS and individualized therapy (10.1111/bjh.19635, Jul 2024) (arachchillage2024guidelinesonthe pages 2-2).

Current applications and real-world implementations - Antithrombotic therapy. For thrombotic APS, long-term anticoagulation with VKA is standard; aspirin may be added in selected arterial/refractory cases; LMWH/heparin is used peri-procedurally and in pregnancy (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Obstetric APS care. Low-dose aspirin plus LMWH is standard of care; mechanistic understanding of placental inflammation and angiogenic imbalance informs adjunctive strategies (10.3390/ijms24043195) (d’ippolito2023antiphospholipidsyndromein pages 4-5). - Targeted adjuncts. Hydroxychloroquine (HCQ) and statins are considered adjuncts in selected patients (statins: antithrombotic pleiotropy impacting platelet signaling and endothelial inflammation) (10.1111/bjh.19635; 10.3390/cells14050353, Feb 2025) (arachchillage2024guidelinesonthe pages 2-2, bucci2025statinsasan pages 2-4). Complement inhibition (e.g., eculizumab) is employed in refractory situations such as CAPS per expert guidance (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2).

Expert opinions and analysis (authoritative sources) - British Journal of Haematology guidelines (2024) synthesize that aPL positivity is “necessary but insufficient,” emphasizing complement, NETs, and a two-hit pathogenesis; VKA remains mainstay for thrombotic APS (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Systems-level omics reinforce immunothrombosis: proteomics and RNA-seq document complement, IFN, and neutrophil/NET pathways in APS tissues and blood (10.1093/rheumatology/keae397; 10.3389/fimmu.2025.1676578) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, pine2025aproteomicmap pages 1-2).

Relevant statistics and data from recent studies - APS kidney RNA-seq: C3 (logFC 2.25, P=1.58×10−5), C4A (2.17, P=2.69×10−6), C4B (2.135, P=3.7×10−6) upregulated; nine IFN-regulated genes up in APS vs. controls; 13/15 NETs-related genes higher in APS (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - IFN signature panels: an 11 IFN-induced gene set (e.g., IFI6/IFI44/RSAD2/MX1) distinguished APS from controls; IFN signatures associated with thrombosis and preeclampsia (10.1093/rheumatology/kead575, Feb 2024) (lopezpedrera2024newadvancesin pages 4-5).

Key concepts and definitions (current understanding) - aPL: Autoantibodies (lupus anticoagulant, anti-cardiolipin IgG/IgM, anti-β2GPI IgG/IgM) that target phospholipid-binding proteins, especially β2GPI; domain I specificity is highly disease-associated (10.3389/fimmu.2025.1639065) (zhu2025noveladvanceson pages 3-4). - Two-hit hypothesis: aPL provide a prothrombotic priming state; inflammation or vascular stress acts as a second hit precipitating overt thrombosis/CAPS (10.1111/bjh.19635; 10.7759/cureus.66555) (arachchillage2024guidelinesonthe pages 2-2, parepalli2024antiphospholipidsyndromeand pages 2-3). - Immunothrombosis: Integration of coagulation, complement, platelets, neutrophils/NETs, and interferon pathways driving thrombosis and microvascular injury (10.1093/rheumatology/keae397; 10.3389/fimmu.2025.1676578) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, pine2025aproteomicmap pages 1-2).

Evidence table | Mechanistic theme | Key finding | Biological level | Notable players | Source (journal, year) | URL/DOI | |---|---|---|---|---:|---:| | aPL–β2GPI (domain I) & TF upregulation | "Anti-β2GPI (domain I) binds exposed epitope and induces tissue factor (TF) upregulation in monocytes and endothelial cells" | Molecular / cellular | β2GPI (Domain I), anti‑β2GPI (DI), TF (F3), monocytes, endothelial cells | Frontiers in Immunology (2025); Journal of Clinical Medicine (2024) (zhu2025noveladvanceson pages 3-4, celia2024antiphospholipidsyndromeinsights pages 3-5) | 10.3389/fimmu.2025.1639065; 10.3390/jcm13144191 | | Platelet activation pathways | aβ2GPI/β2GPI complexes engage ApoER2, GPIbα and αIIbβ3 → p38/PI3K‑AKT activation, ROS and TXA2 production → platelet aggregation | Cellular | Platelets, ApoER2, GPIbα, αIIbβ3, p38 MAPK, NADPH oxidase | Cells (2025); Frontiers in Immunology (2025) (bucci2025statinsasan pages 2-4, zhu2025noveladvanceson pages 3-4) | 10.3390/cells14050353; 10.3389/fimmu.2025.1639065 | | Endothelial activation gene programs | Endothelial transcriptomes show NF‑κB–driven upregulation of IL‑6, IL‑8, E‑selectin, VCAM‑1, ICAM‑1 and MAPK/TGFβ pathway activation after aPL/β2GPI exposure | Cellular / organ | Endothelial cells, NF‑κB, IL6, IL8, VCAM1, ICAM1, MAPK | Rheumatology (2024); Journal of Clinical Medicine (2024) (lopezpedrera2024newadvancesin pages 1-2, celia2024antiphospholipidsyndromeinsights pages 3-5) | 10.1093/rheumatology/kead575; 10.3390/jcm13144191 | | Complement activation (biomarkers & pathways) | Upregulation/consumption of complement (C3, C4A, C4B) in APS target tissue; complement split products (C3a/C4a) consistent with activation/consumption | Molecular / organ | C3, C4A, C4B, C5a, terminal complement (C5b‑9) | Rheumatology (kidney RNA‑seq, 2024); British Journal of Haematology guidelines (2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, arachchillage2024guidelinesonthe pages 2-2) | 10.1093/rheumatology/keae397; 10.1111/bjh.19635 | | NETs signatures / quantitation | NETs‑related genes (MPO, ELANE, PADI4) and NETosis signatures are increased in APS blood and kidney samples | Molecular / cellular | Neutrophils, MPO, ELANE, PADI4, extracellular histones | Rheumatology (kidney RNA‑seq, 2024); Frontiers in Immunology review (2025) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, zhu2025noveladvanceson pages 1-3) | 10.1093/rheumatology/keae397; 10.3389/fimmu.2025.1639065 | | Type I interferon transcriptomic signatures (blood & kidney) | "Type I IFN‑regulated genes (IFI6, IFI44, MX1, OAS1) are upregulated across the APS spectrum" (blood and kidney transcriptomes) | Molecular / cellular | IFI6, IFI44, IFI44L, MX1, OAS1, RSAD2 | Rheumatology (IFN signatures, 2024); Rheumatology kidney transcriptome (2024) (lopezpedrera2024newadvancesin pages 5-6, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6) | 10.1093/rheumatology/kead575; 10.1093/rheumatology/keae397 | | Obstetric APS — placental lesions & mechanisms | Placental findings: infarction, decidual vasculopathy, ↑ syncytial knots, ↓ vasculosyncytial membranes; trophoblast dysfunction, altered uNK cell function and angiogenesis | Tissue / organ | Trophoblasts, uterine NK cells, spiral arteries, sFlt‑1/PlGF imbalance | Int J Mol Sci (2023); Rheumatology (2024) (d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2) | 10.3390/ijms24043195; 10.1093/rheumatology/kead575 | | Two‑hit hypothesis (triggers) | aPL constitute a "first hit" creating prothrombotic milieu; infection, pregnancy, surgery, or endothelial injury act as a "second hit" precipitating thrombosis/CAPS | Systemic / clinical | aPLs, infections (e.g., viral), pregnancy, endothelial injury | Cureus review (2024); BJH guidelines (2024) (parepalli2024antiphospholipidsyndromeand pages 2-3, arachchillage2024guidelinesonthe pages 2-2) | 10.7759/cureus.66555; 10.1111/bjh.19635 | | Platelet–complement crosstalk | Platelet activation correlates with lectin pathway proteins and C3dg; platelet–complement interactions modulate thromboinflammatory responses | Cellular / molecular | Platelets, MASP‑2, lectin pathway proteins, C3dg, C3 | Cells/Rheumatology summaries and guidelines (2023–2024) (bucci2025statinsasan pages 2-4, arachchillage2024guidelinesonthe pages 2-2) | 10.3390/cells14050353; 10.1111/bjh.19635 | | Biomarkers — anti‑β2GPI‑DI, aPS/PT, triple positivity | Anti‑β2GPI‑domain I shows high specificity for APS; aPS/PT associates with obstetric loss; triple/double aPL positivity increases thrombotic/obstetric risk | Clinical / molecular | anti‑β2GPI‑DI, aPS/PT, LA, aCL (IgG/IgM) | Front Immunol / J Clin Med summaries (2025, 2024) (zhu2025noveladvanceson pages 3-4, celia2024antiphospholipidsyndromeinsights pages 3-5) | 10.3389/fimmu.2025.1639065; 10.3390/jcm13144191 | | Therapeutic implications / targets | Standard: anticoagulation (LMWH/heparin, VKA) ± aspirin; adjuncts with HCQ, statins; complement inhibitors (eculizumab) for refractory/CAPS cases | Clinical | Heparin/LMWH, VKA, aspirin, hydroxychloroquine, statins, eculizumab | BJH guidelines (2024); Cells (statins review, 2025) (arachchillage2024guidelinesonthe pages 2-2, bucci2025statinsasan pages 2-4) | 10.1111/bjh.19635; 10.3390/cells14050353 |

Table: Concise, sourced evidence summarizing key mechanistic themes in antiphospholipid syndrome (APS), with biological level, primary players, and citations to the supporting literature (context IDs). This table is designed for rapid knowledge‑base ingestion and mechanistic mapping.

Key Molecular Players and Ontology-aligned annotations - Genes/Proteins (HGNC): APOER2/LRP8; GP1BA; ITGA2B/ITGB3; F3 (Tissue factor); TFPI; SERPINE1 (PAI-1); PROS1 (Protein S); C3, C4A, C4B; IFI6, IFI44, MX1, OAS1, RSAD2; MPO, ELANE, PADI4; VCAM1, ICAM1, SELE; NFKB1 (bucci2025statinsasan pages 2-4, zhu2025noveladvanceson pages 3-4, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, lopezpedrera2024newadvancesin pages 1-2, lopezpedrera2024newadvancesin pages 4-5). - Chemical entities (CHEBI): Thromboxane A2; Prostacyclin; Reactive oxygen species; Heparin; Warfarin; Acetylsalicylic acid (aspirin) (bucci2025statinsasan pages 2-4, arachchillage2024guidelinesonthe pages 2-2). - Cell types (CL): Platelet; Endothelial cell; Monocyte; Neutrophil; Trophoblast; Uterine NK cell (bucci2025statinsasan pages 2-4, d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2). - Anatomical locations (UBERON): Blood vessel endothelium; Placenta; Kidney (nephron); Decidua; Spiral artery (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2). - Biomarkers: anti-β2GPI (domain I); lupus anticoagulant; anti-cardiolipin; anti-phosphatidylserine/prothrombin (aPS/PT); complement split products (C3a/C4a); IFN gene signature panels (zhu2025noveladvanceson pages 3-4, d’ippolito2023antiphospholipidsyndromein pages 4-5, celia2024antiphospholipidsyndromeinsights pages 3-5, lopezpedrera2024newadvancesin pages 4-5).

Biological Processes (GO-style terms) disrupted - Blood coagulation and regulation of thrombin generation; extrinsic coagulation via tissue factor; fibrinolysis and regulation of plasminogen activation (bucci2025statinsasan pages 2-4, celia2024antiphospholipidsyndromeinsights pages 3-5). - Complement activation (classical/lectin/alternative collectively implicated by C3/C4 upregulation and C3a/C4a split products) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, celia2024antiphospholipidsyndromeinsights pages 3-5). - Neutrophil activation and neutrophil extracellular trap formation (NETosis) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, arachchillage2024guidelinesonthe pages 2-2). - Type I interferon signaling; innate immune activation; TLR signaling pathways (TLR4/TLR7/8) (lopezpedrera2024newadvancesin pages 4-5, zhu2025noveladvanceson pages 3-4). - Endothelial activation: NF-κB signaling, cytokine production (IL-6/IL-8), cell adhesion (VCAM-1/ICAM-1/E-selectin) (lopezpedrera2024newadvancesin pages 1-2). - Placental development and angiogenesis; trophoblast differentiation and invasion; decidual vasculature remodeling (d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2).

Cellular Components implicated - Plasma membrane complexes (β2GPI–aPL complexes on endothelial cells, platelets, monocytes); lipid rafts; integrin αIIbβ3 (bucci2025statinsasan pages 2-4, celia2024antiphospholipidsyndromeinsights pages 3-5). - Extracellular space: NETs (DNA–histone complexes with MPO/ELANE), complement components (C3, C4), and thrombin/fibrin (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, arachchillage2024guidelinesonthe pages 2-2). - Endothelial Weibel–Palade bodies/adhesion molecule-rich surfaces; platelet granules (lopezpedrera2024newadvancesin pages 1-2, bucci2025statinsasan pages 2-4).

Disease progression: sequence of events - Initiation: Persistent aPL (often triple-positive) bind β2GPI/prothrombin on cell surfaces; endothelial cells, monocytes, platelets are primed; IFN/TLR pathways heighten inflammatory tone (zhu2025noveladvanceson pages 3-4, lopezpedrera2024newadvancesin pages 4-5). - Trigger (“second hit”): Infection, surgery, pregnancy, or vascular injury causes overt cell activation, TF exposure, complement amplification, and NETosis (arachchillage2024guidelinesonthe pages 2-2, parepalli2024antiphospholipidsyndromeand pages 2-3). - Thromboinflammation: Thrombin generation increases; platelets aggregate (ApoER2/GPIbα/αIIbβ3; PI3K–AKT, p38); endothelium upregulates adhesion molecules and cytokines; complement split products (C3a/C5a) amplify (bucci2025statinsasan pages 2-4, lopezpedrera2024newadvancesin pages 1-2, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - Clinical manifestation: Macrovascular thrombosis (venous/arterial) or microvascular occlusion (e.g., APS nephropathy); obstetric morbidity via placental dysfunction and insufficiency (arachchillage2024guidelinesonthe pages 2-2, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, d’ippolito2023antiphospholipidsyndromein pages 4-5). - Severe phenotype: Catastrophic APS with disseminated microvascular thromboses, often following a strong trigger and with complement involvement (arachchillage2024guidelinesonthe pages 2-2).

Phenotypic manifestations and mechanistic links - Thrombosis (HP:0001907 venous; HP:0005110 arterial): TF-driven thrombin generation, platelet hyperreactivity, NETs and complement amplification (bucci2025statinsasan pages 2-4, arachchillage2024guidelinesonthe pages 2-2, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - Obstetric complications: Recurrent pregnancy loss (HP:0005268), preeclampsia (HP:0002372), fetal growth restriction (HP:0001511), placental insufficiency (HP:0001987) due to trophoblast dysfunction, decidual vasculopathy, and placental inflammation (10.3390/ijms24043195; 10.1093/rheumatology/kead575) (d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2). - APS nephropathy (HP:0033411 microangiopathy): Complement/IFN/NETs-related transcriptional programs in kidney (10.1093/rheumatology/keae397) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - CAPS: Multiorgan microvascular thromboses with high mortality; driven by aPL with strong second hits and complement activation (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2).

Direct quotes supporting key statements - “Interferon (IFN) alpha/beta signalling was revealed by Reactome” in APS kidney transcriptomes; complement genes C3/C4A/C4B were upregulated (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - “Upregulation of IFN-related genes in patients with APS” was observed across whole blood, PBMCs and neutrophils; a PBMC panel identified “a distinct signature comprising 11 IFN-induced genes” (10.1093/rheumatology/kead575, Feb 2024) (lopezpedrera2024newadvancesin pages 4-5).

Therapeutic implications/targets informed by pathophysiology - Anticoagulation (VKA) remains first-line for thrombotic APS; heparin/LMWH and aspirin applied per risk/setting (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Targeting cell activation and inflammation: HCQ as adjunct; statins for selected high-risk thrombotic APS to attenuate platelet/endothelial activation; investigational complement inhibition for refractory/CAPS (10.1111/bjh.19635; 10.3390/cells14050353) (arachchillage2024guidelinesonthe pages 2-2, bucci2025statinsasan pages 2-4).

Evidence items (PMIDs/DOIs/URLs; publication dates) - Arachchillage DJ et al. Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology. Jul 2024. doi:10.1111/bjh.19635; https://doi.org/10.1111/bjh.19635 (arachchillage2024guidelinesonthe pages 2-2). - Tektonidou MG et al. Kidney whole-transcriptome profiling… Rheumatology (Oxford). Aug 2024. doi:10.1093/rheumatology/keae397; https://doi.org/10.1093/rheumatology/keae397 (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - López‑Pedrera C et al. New advances in genomics and epigenetics in APS. Rheumatology. Feb 2024. doi:10.1093/rheumatology/kead575; https://doi.org/10.1093/rheumatology/kead575 (lopezpedrera2024newadvancesin pages 1-2, lopezpedrera2024newadvancesin pages 4-5). - Celia AI et al. Antiphospholipid syndrome: insights… Journal of Clinical Medicine. Jul 2024. doi:10.3390/jcm13144191; https://doi.org/10.3390/jcm13144191 (celia2024antiphospholipidsyndromeinsights pages 3-5). - Zhu Q‑N et al. Novel advances… Frontiers in Immunology. Aug 2025. doi:10.3389/fimmu.2025.1639065; https://doi.org/10.3389/fimmu.2025.1639065 (zhu2025noveladvanceson pages 3-4, zhu2025noveladvanceson pages 1-3). - Bucci T et al. Statins as an adjunctive antithrombotic agent in T‑APS. Cells. Feb 2025. doi:10.3390/cells14050353; https://doi.org/10.3390/cells14050353 (bucci2025statinsasan pages 2-4). - Pine A et al. A proteomic map of thromboinflammatory signatures in APS. Frontiers in Immunology. Oct 2025. doi:10.3389/fimmu.2025.1676578; https://doi.org/10.3389/fimmu.2025.1676578 (pine2025aproteomicmap pages 1-2). - D’Ippolito S et al. APS in pregnancy: pathogenetic mechanisms. Int J Mol Sci. Feb 2023. doi:10.3390/ijms24043195; https://doi.org/10.3390/ijms24043195 (d’ippolito2023antiphospholipidsyndromein pages 4-5).

Note on scope and gaps - Where detailed quantitative NET biomarker cutoffs and specific complement split-product levels in APS cohorts are needed, additional prospective studies are emerging but were beyond the scope of the cited transcripts/guidelines.

References

(arachchillage2024guidelinesonthe pages 2-2): Deepa J. Arachchillage, Sean Platton, Kieron Hickey, Justin Chu, Matthew Pickering, Peter Sommerville, Peter MacCallum, and Karen Breen. Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 205:855-880, Jul 2024. URL: https://doi.org/10.1111/bjh.19635, doi:10.1111/bjh.19635. This article has 39 citations and is from a domain leading peer-reviewed journal.
(parepalli2024antiphospholipidsyndromeand pages 2-3): Avinash Parepalli, Rajesh Sarode, Sunil Kumar, Manikanta Nelakuditi, and M Jayanth Kumar. Antiphospholipid syndrome and catastrophic antiphospholipid syndrome: a comprehensive review of pathogenesis, clinical features, and management strategies. Cureus, Aug 2024. URL: https://doi.org/10.7759/cureus.66555, doi:10.7759/cureus.66555. This article has 10 citations and is from a poor quality or predatory journal.
(celia2024antiphospholipidsyndromeinsights pages 3-5): Alessandra Ida Celia, Mattia Galli, Silvia Mancuso, Cristiano Alessandri, Giacomo Frati, Sebastiano Sciarretta, and Fabrizio Conti. Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations. Journal of Clinical Medicine, 13:4191, Jul 2024. URL: https://doi.org/10.3390/jcm13144191, doi:10.3390/jcm13144191. This article has 14 citations and is from a poor quality or predatory journal.
(zhu2025noveladvanceson pages 3-4): Qing-Nan Zhu, Xiang-Bo Qi, Shu-Wei Ren, Yu-Ye Li, Ze-Wen Yan, Yu Sun, Yan Shi, Qing-Si Wen, Mao-Mao Wu, and Da-Peng Wang. Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome. Frontiers in Immunology, Aug 2025. URL: https://doi.org/10.3389/fimmu.2025.1639065, doi:10.3389/fimmu.2025.1639065. This article has 3 citations and is from a peer-reviewed journal.
(bucci2025statinsasan pages 2-4): Tommaso Bucci, Danilo Menichelli, Ilaria Maria Palumbo, Daniele Pastori, Paul R. J. Ames, Gregory Y. H. Lip, and Pasquale Pignatelli. Statins as an adjunctive antithrombotic agent in thrombotic antiphospholipid syndrome: mechanisms and clinical implications. Cells, 14:353, Feb 2025. URL: https://doi.org/10.3390/cells14050353, doi:10.3390/cells14050353. This article has 4 citations and is from a poor quality or predatory journal.
(lopezpedrera2024newadvancesin pages 1-2): Chary López-Pedrera, Tomás Cerdó, Elizabeth C Jury, Laura Muñoz-Barrera, Alejandro Escudero-Contreras, M A Aguirre, and Carlos Pérez-Sánchez. New advances in genomics and epigenetics in antiphospholipid syndrome. Rheumatology, 63:SI14-SI23, Feb 2024. URL: https://doi.org/10.1093/rheumatology/kead575, doi:10.1093/rheumatology/kead575. This article has 8 citations and is from a peer-reviewed journal.
(tektonidou2024kidneywholetranscriptomeprofiling pages 4-6): Maria G Tektonidou, Kleio-Maria Verrou, Harikleia Gakiopoulou, Menelaos Manoloukos, Panagiotis Lembessis, Pantelis Hatzis, and Petros P Sfikakis. Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and nets-related gene expression. Rheumatology (Oxford, England), 63:3184-3190, Aug 2024. URL: https://doi.org/10.1093/rheumatology/keae397, doi:10.1093/rheumatology/keae397. This article has 9 citations.
(lopezpedrera2024newadvancesin pages 4-5): Chary López-Pedrera, Tomás Cerdó, Elizabeth C Jury, Laura Muñoz-Barrera, Alejandro Escudero-Contreras, M A Aguirre, and Carlos Pérez-Sánchez. New advances in genomics and epigenetics in antiphospholipid syndrome. Rheumatology, 63:SI14-SI23, Feb 2024. URL: https://doi.org/10.1093/rheumatology/kead575, doi:10.1093/rheumatology/kead575. This article has 8 citations and is from a peer-reviewed journal.
(d’ippolito2023antiphospholipidsyndromein pages 4-5): Silvia D’Ippolito, Greta Barbaro, Carmela Paciullo, Chiara Tersigni, Giovanni Scambia, and Nicoletta Di Simone. Antiphospholipid syndrome in pregnancy: new and old pathogenetic mechanisms. International Journal of Molecular Sciences, 24:3195, Feb 2023. URL: https://doi.org/10.3390/ijms24043195, doi:10.3390/ijms24043195. This article has 60 citations and is from a poor quality or predatory journal.
(pine2025aproteomicmap pages 1-2): Alexander Pine, Ayesha Butt, Laura Andreoli, Jason S. Knight, Maria Gerosa, Irene Cecchi, D. Ware Branch, Rosario Lopez-Pedrera, H. Michael Belmont, Nina Kello, Michelle Petri, Ricard Cervera, Vittorio Pengo, Pier Luigi Meroni, Hannah Cohen, Rohan Willis, Maria Laura Bertolccini, George Goshua, Sean Gu, John Hwa, Alfred I. Lee, Doruk Erkan, and Anish V. Sharda. A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (aps action) registry. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1676578, doi:10.3389/fimmu.2025.1676578. This article has 0 citations and is from a peer-reviewed journal.
(zhu2025noveladvanceson pages 1-3): Qing-Nan Zhu, Xiang-Bo Qi, Shu-Wei Ren, Yu-Ye Li, Ze-Wen Yan, Yu Sun, Yan Shi, Qing-Si Wen, Mao-Mao Wu, and Da-Peng Wang. Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome. Frontiers in Immunology, Aug 2025. URL: https://doi.org/10.3389/fimmu.2025.1639065, doi:10.3389/fimmu.2025.1639065. This article has 3 citations and is from a peer-reviewed journal.
(lopezpedrera2024newadvancesin pages 5-6): Chary López-Pedrera, Tomás Cerdó, Elizabeth C Jury, Laura Muñoz-Barrera, Alejandro Escudero-Contreras, M A Aguirre, and Carlos Pérez-Sánchez. New advances in genomics and epigenetics in antiphospholipid syndrome. Rheumatology, 63:SI14-SI23, Feb 2024. URL: https://doi.org/10.1093/rheumatology/kead575, doi:10.1093/rheumatology/kead575. This article has 8 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Definitions

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Related Datasets

Source YAML

References & Deep Research

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)